mitomycin has been researched along with Carcinoma, Transitional Cell in 381 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravesical chemotherapy using mitomycin C in patients with superficial bladder cancer after transurethral resection (TUR) has proved to be highly effective in preventing tumor recurrences and/or progression." | 10.16 | Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy. ( DeBruyne, FM; van der Meijden, AP, 1988) |
| "From those 11 studies, it is shown that intravesical chemotherapy using Epirubicin and Mitomycin-C following TURB showed significant decrease of recurrence rate of bladder cancer even to progression of the disease compared to TURB alone (p<0." | 9.22 | Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis. ( Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP, 2022) |
| "We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up." | 9.12 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. ( El-Ganzoury, HM; El-Ghobashy, S; El-Leithy, TR; Roshdy, MM, 2007) |
| "The rationale for combining anticancer drugs has not been applied consistently to use of intravesical agents for treatment of superficial bladder cancer, for which immunotherapeutic BCG and chemotherapeutic mitomycin seem to be a potentially effective combination." | 9.12 | Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. ( Attisani, F; Capelli, G; De Carolis, A; Di Stasi, SM; Giannantoni, A; Giurioli, A; Stephen, RL; Storti, L; Valenti, M; Vespasiani, G; Zampa, G, 2006) |
| "We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial." | 9.09 | The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study. ( Bodrogi, I; Határ, A; Kiss, A; Kiss, L; Kondás, J; Lukács, T; Szeldeli, P; Törzsök, F, 1999) |
| "To elucidate the most efficient topical therapy for carcinoma in situ of the bladder, the efficacy of intravesical mitomycin C plus doxorubicin therapy was compared with bacillus Calmette-Guerin (BCG) therapy." | 9.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "We determined the role, if any, of 1 and 5 instillations of intravesical mitomycin C in the treatment of newly diagnosed superficial bladder cancer." | 9.08 | The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. ( Benyon, LL; Fellows, J; Freedman, LS; Grigor, KM; Hall, RR; Hargreave, TB; Lallemand, G; Munson, K; Newling, DW; Parmar, MK; Richards, B; Robinson, MR; Rose, MB; Smith, PH; Tolley, DA; Whelan, P; Williams, JL, 1996) |
| "We study toxicity and efficacy of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin (BCG) in patients with intermediate or high risk superficial bladder cancer compared to the use of intravesical mitomycin C alone." | 9.08 | Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. ( Caris, CT; Debruyne, FM; Mungan, NA; Witjes, JA; Witjes, WP, 1998) |
| "We compared intravesical instillations with mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice, and BCG-RIVM in patients with pTa-pT1 papillary carcinoma and primary carcinoma in situ (CIS) of the bladder." | 9.07 | A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. ( Debruyne, FM; Doesburg, W; Schaafsma, HE; vd Meijden, AP; Witjes, JA; Witjes, WP, 1993) |
| "Both intravesical mitomycin C (MMC) and bacillus Calmette-Guérin (BCG; Pasteur strain F) were effective in the present prospective randomized multicenter study consisting of 91 patients with frequently recurrent superficial (Ta-T1) bladder cancer." | 9.07 | Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. ( Alfthan, O; Hansson, E; Jauhiainen, K; Juusela, H; Kanerva, K; Korhonen, H; Permi, J; Rintala, E; Sotarauta, M; Vaalasti, T, 1991) |
| " Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate- or high-risk non-muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain." | 9.05 | Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Dahm, P; Dersch, R; Draeger, DL; Jensen, K; Kilian, S; Krabbe, LM; Kunath, F; Meerpohl, JJ; Schmidt, S, 2020) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 9.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "To undertake a systematic review and meta-analysis comparing intravesical mitomycin C and Bacillus Calmette-Guerin in terms of tumour recurrence, disease progression and overall survival in Ta and T1 bladder cancer." | 8.82 | Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Court, JB; Kynaston, H; Mason, M; Shelley, MD; Wilt, TJ, 2003) |
| "Perioperative instillation of mitomycin-C (MMC) has shown effectiveness in reducing the recurrence of low-grade non-muscle invasive bladder cancer (NMIBC)." | 8.31 | Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer. ( Baniel, J; Golan, S; Halstuch, D; Karchever, I; Kedar, D; Lotan, P; Rubinshtein, D, 2023) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 7.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| "To identify whether integrinβ1 subunit is responsible for the resistance of bladder cancer cell to the therapeutic drug mitomycin-C (MMC), when grown on fibronectin (FN)." | 7.78 | Engagement of integrinβ1 induces resistance of bladder cancer cells to mitomycin-C. ( Li, T; Pan, CW; Shen, ZJ; Zhang, CJ; Zhang, MG; Zhong, S, 2012) |
| "• To examine, using in vitro and in vivo models, the largely unexamined effect of mitomycin C (MMC), an effective intravesical treatment for superficial bladder cancer and carcinoma in situ, on expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2), which mediates many of the angiogenic properties of VEGF." | 7.77 | Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. ( Degrado, J; Hittelman, AB; Kaimakliotis, HZ; Verma, A; Weiss, RM; Wheeler, MA, 2011) |
| "The human bladder cancer cell lines EJ28 and 5637 were transiently transfected with 3 antiVEGF AS-ODNs, followed by incubation with 3 doses of mitomycin C, gemcitabine or cisplatin CT." | 7.73 | Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin. ( Förster, Y; Fuessel, S; Kotzsch, M; Kraemer, K; Krause, S; Meye, A; Schmidt, U; Schwenzer, B; Wirth, MP, 2005) |
| "Transurethral resection followed by instillation of chemotherapeutic agents such as mitomycin is considered as standard therapy in recurrent superficial bladder cancer." | 7.73 | Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin. ( Fechner, G; Müller, SC; Pocha, K; Schmidt, D, 2006) |
| "The enhancing effects of Smac gene on the mitomycin C-induced apoptosis of the bladder cancer cell line T24 were investigated." | 7.73 | Smac/DIABLO promotes mitomycin C-induced apoptosis of bladder cancer T24 cells. ( Fuqing, Z; Tong, Q; Wang, L; Zheng, L, 2006) |
| "To compare the tumoricidal efficacy of meglumine gamma-linolenic acid (MeGLA), mitomycin C, epirubicin and water on two urothelial cell lines, and to establish the effect of serum protein levels derived from bladder cancer resection craters on the action of these agents." | 7.70 | Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent? ( Birch, BR; Cooper, AJ; Foley, SJ; Jennings, AM; Solomon, LZ, 1998) |
| "Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989." | 7.69 | Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Viganò, L, 1994) |
| " Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along with its mitomycin C-resistant counterpart J82/MMC." | 7.69 | Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. ( Allman, R; Datta, SN; Loh, C; Mason, M; Matthews, PN, 1997) |
| "Bladder wall calcification is a rare complication of intravesical therapy of superficial bladder cancer with Mitomycin C." | 7.68 | Incrusted cystitis after intravesical mitomycin C treatment. ( Algado, M; Botella, R; Llopis, M; Moreno, J, 1993) |
| "The effect of intravesical instillation of 200,000 IU hyaluronidase in addition to mitomycin C as chemoprophylaxis of superficial bladder cancer was evaluated." | 7.68 | Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. ( Höbarth, K; Maier, U; Marberger, M, 1992) |
| "A total of 20 patients received intravesical bacillus Calmette-Guerin (BCG) or mitomycin C for the treatment of carcinoma in situ following previous pelvic radiation therapy." | 7.68 | Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. ( Pisters, LL; Tykochinsky, G; Wajsman, Z, 1991) |
| "Calcification of the bladder wall associated with intravesical mitomycin C for the treatment of superficial bladder cancer is a rare complication." | 7.67 | Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. ( Badalament, RA; Drago, JR; Drago, PC; Lucas, J, 1989) |
| "A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer." | 7.67 | Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. ( Soloway, MS, 1985) |
| "Twenty-three patients with histologically proven superficial bladder cancer (Tis, Ta, T1) were treated with intravesical instillations of Mitomycin C at a dose of 20 mg in 20 ml of water 3 times weekly for 21 instillations." | 7.66 | A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. ( Green, DF; Harrison, GS; Newling, DW; Richards, B; Robinson, MR; Smith, PH, 1983) |
| "Intravesical chemotherapy using mitomycin C in patients with superficial bladder cancer after transurethral resection (TUR) has proved to be highly effective in preventing tumor recurrences and/or progression." | 6.16 | Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy. ( DeBruyne, FM; van der Meijden, AP, 1988) |
| "In patients with superficial bladder cancer, the occurrence of primary carcinoma in situ was significantly greater in patients with the AA genotype compared with those with the GA or GG genotypes (P = 0." | 5.32 | Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. ( Habuchi, T; Higashi, S; Ito, M; Kamoto, T; Nishiyama, H; Ogawa, O; Tsuchiya, N; Wang, L; Watanabe, J, 2004) |
| "Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients." | 5.30 | BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| "Eosinophilic cystitis is an unusual form of cystitis which is characterized by irritative voiding symptoms and haematuria." | 5.29 | Eosinophilic cystitis induced by mitomycin-C. ( Apaydin, E; Gürsan, A; Kandiloğlu, G; Ozyurt, C; Ulker, V, 1996) |
| " Combination with mitomycin C or interferon-alpha-2b potentiated the cytostatic effect." | 5.28 | Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. ( Alfthan, O; Jauhiainen, K; Kaasinen, E; Lähde, M; Nurmi, M; Rajala, P; Rintala, E, 1992) |
| "From those 11 studies, it is shown that intravesical chemotherapy using Epirubicin and Mitomycin-C following TURB showed significant decrease of recurrence rate of bladder cancer even to progression of the disease compared to TURB alone (p<0." | 5.22 | Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis. ( Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP, 2022) |
| "To determine the safety and toxicities of sequential MMC (mitomycin C) + BCG (bacillus Calmette-Guérin) in patients with non-muscle-invasive bladder cancer (NMIBC) and explore evidence for potentiation of BCG activity by MMC." | 5.20 | Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. ( Curiel, TJ; Hernandez, J; Hugen, CM; Hurez, V; Jha, MK; Morales, EE; Svatek, RS; Tseng, TY; Zhao, XR, 2015) |
| "The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin." | 5.17 | Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. ( Ajani, JA; Benson, AB; Gunderson, LL; Haddock, MG; Mayer, RJ; Moughan, J; Pedersen, JE; Rich, TA; Thomas, CR; Willett, CG; Winter, KA, 2013) |
| "A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811." | 5.17 | RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ( Esthappan, J; Goodyear, MD; Haddock, MG; Kachnic, LA; Myerson, RJ; Parikh, PJ; Rotman, M; Safran, H; Willett, CG; Willins, J; Winter, K, 2013) |
| " Bleeding, infection, and fever were most common with adjuvant treatment (BCG or mitomycin)." | 5.12 | Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma. ( Linehan, J; Schoenberg, M; Seltzer, E; Smith, AB; Thacker, K, 2021) |
| "We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up." | 5.12 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. ( El-Ganzoury, HM; El-Ghobashy, S; El-Leithy, TR; Roshdy, MM, 2007) |
| "The rationale for combining anticancer drugs has not been applied consistently to use of intravesical agents for treatment of superficial bladder cancer, for which immunotherapeutic BCG and chemotherapeutic mitomycin seem to be a potentially effective combination." | 5.12 | Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. ( Attisani, F; Capelli, G; De Carolis, A; Di Stasi, SM; Giannantoni, A; Giurioli, A; Stephen, RL; Storti, L; Valenti, M; Vespasiani, G; Zampa, G, 2006) |
| "We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer." | 5.11 | Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004) |
| "To report a phase-1 study of patients with recurrent superficial bladder cancer treated with photodynamic therapy (PDT) using sequential mitomycin C and 5-aminolaevulinic acid (ALA)." | 5.11 | A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. ( Allman, R; Datta, SN; French, AJ; Mason, MD; Matthews, PN; Skyrme, RJ, 2005) |
| "Ablative therapy with interferon-alpha was less effective than mitomycin-C in patients with superficial bladder cancer." | 5.10 | A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. ( Malmström, PU, 2002) |
| "We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial." | 5.09 | The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study. ( Bodrogi, I; Határ, A; Kiss, A; Kiss, L; Kondás, J; Lukács, T; Szeldeli, P; Törzsök, F, 1999) |
| ", placement of the drug directly in the bladder) with mitomycin C is beneficial for patients with superficial bladder cancer who are at high risk of recurrence, but standard therapy is empirically based and patient response rates have been variable, in part because of inadequate drug delivery." | 5.09 | Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. ( Au, JL; Badalament, RA; Chin, JL; Harbrecht, JD; Lerner, SP; Miles, BJ; Pollifrone, DL; Venema, PL; Warner, JA; Wientjes, MG; Young, DC, 2001) |
| "To elucidate the most efficient topical therapy for carcinoma in situ of the bladder, the efficacy of intravesical mitomycin C plus doxorubicin therapy was compared with bacillus Calmette-Guerin (BCG) therapy." | 5.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "We determined the role, if any, of 1 and 5 instillations of intravesical mitomycin C in the treatment of newly diagnosed superficial bladder cancer." | 5.08 | The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. ( Benyon, LL; Fellows, J; Freedman, LS; Grigor, KM; Hall, RR; Hargreave, TB; Lallemand, G; Munson, K; Newling, DW; Parmar, MK; Richards, B; Robinson, MR; Rose, MB; Smith, PH; Tolley, DA; Whelan, P; Williams, JL, 1996) |
| "The authors present the results of two parallel phase II trials, instituted by the EORTC Genito-Urinary Group in 1986, whose aims were to assess the tolerability and ablative capacity of mitomycin C (study 30864) and epirubicin (study 30869) in patients with multiple primary or recurrent Ta-T1 bladder cancer." | 5.08 | Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. ( Bono, AV; Denis, L; Hall, RR; Lovisolo, JA; Sylvester, R, 1996) |
| "We study toxicity and efficacy of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin (BCG) in patients with intermediate or high risk superficial bladder cancer compared to the use of intravesical mitomycin C alone." | 5.08 | Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. ( Caris, CT; Debruyne, FM; Mungan, NA; Witjes, JA; Witjes, WP, 1998) |
| "A randomized and placedo-controlled trial on intravesical N-CWS instillation versus mitomycin-C(MMC) therapy for recurrence prevention in postopenative bladder cancer patients was carried out." | 5.08 | [Long-term results of intravesical N-CWS instillation to prevent recurrence after surgery for bladder cancer]. ( Chen, S; Lin, Z; Xu, E, 1997) |
| "We compared intravesical instillations with mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice, and BCG-RIVM in patients with pTa-pT1 papillary carcinoma and primary carcinoma in situ (CIS) of the bladder." | 5.07 | A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. ( Debruyne, FM; Doesburg, W; Schaafsma, HE; vd Meijden, AP; Witjes, JA; Witjes, WP, 1993) |
| "Both intravesical mitomycin C (MMC) and bacillus Calmette-Guérin (BCG; Pasteur strain F) were effective in the present prospective randomized multicenter study consisting of 91 patients with frequently recurrent superficial (Ta-T1) bladder cancer." | 5.07 | Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. ( Alfthan, O; Hansson, E; Jauhiainen, K; Juusela, H; Kanerva, K; Korhonen, H; Permi, J; Rintala, E; Sotarauta, M; Vaalasti, T, 1991) |
| "A prospective randomized clinical trial was conducted by the National Bladder Cancer Group to compare thiotepa and mitomycin C in ablating residual Ta, T1 and TIS transitional cell carcinoma of the bladder." | 5.06 | Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. ( Barton, B; Hazra, T; Heney, NM; Koontz, WW; Soloway, M; Trump, DL; Weinstein, RS, 1988) |
| " Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate- or high-risk non-muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain." | 5.05 | Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Dahm, P; Dersch, R; Draeger, DL; Jensen, K; Kilian, S; Krabbe, LM; Kunath, F; Meerpohl, JJ; Schmidt, S, 2020) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 5.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "To undertake a systematic review and meta-analysis comparing intravesical mitomycin C and Bacillus Calmette-Guerin in terms of tumour recurrence, disease progression and overall survival in Ta and T1 bladder cancer." | 4.82 | Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Court, JB; Kynaston, H; Mason, M; Shelley, MD; Wilt, TJ, 2003) |
| "Perioperative instillation of mitomycin-C (MMC) has shown effectiveness in reducing the recurrence of low-grade non-muscle invasive bladder cancer (NMIBC)." | 4.31 | Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer. ( Baniel, J; Golan, S; Halstuch, D; Karchever, I; Kedar, D; Lotan, P; Rubinshtein, D, 2023) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 3.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| "To examine the effectiveness of mitomycin-C and chemo-hyperthermia in combination for patients with high-risk non-muscle-invasive bladder cancer." | 3.81 | Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer. ( Akarken, I; Cakmak, O; Celik, O; Divrik, RT; Ekin, RG; Ilbey, YO; Tarhan, H; Zorlu, F, 2015) |
| "Between 1976 and 2008, 116 patients with T2 node-negative anal cancer were treated curatively with RT alone (n=48) or by combined chemoradiation therapy (CRT) (n=68) incorporating mitomycin C and 5-fluorouracil." | 3.79 | Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. ( Allal, AS; Betz, M; Bieri, S; Ris, F; Roche, B; Roth, AD; Zilli, T, 2013) |
| "To identify whether integrinβ1 subunit is responsible for the resistance of bladder cancer cell to the therapeutic drug mitomycin-C (MMC), when grown on fibronectin (FN)." | 3.78 | Engagement of integrinβ1 induces resistance of bladder cancer cells to mitomycin-C. ( Li, T; Pan, CW; Shen, ZJ; Zhang, CJ; Zhang, MG; Zhong, S, 2012) |
| "• To examine, using in vitro and in vivo models, the largely unexamined effect of mitomycin C (MMC), an effective intravesical treatment for superficial bladder cancer and carcinoma in situ, on expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2), which mediates many of the angiogenic properties of VEGF." | 3.77 | Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. ( Degrado, J; Hittelman, AB; Kaimakliotis, HZ; Verma, A; Weiss, RM; Wheeler, MA, 2011) |
| "Treatment of HTB5 and HTB9 bladder cancer cells for 24 to 72 hours with valproic acid and mitomycin C resulted in concentration and time dependent decreases in viability and proliferation." | 3.77 | Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro. ( Deb, AA; Koul, HK; Koul, S; Kumar, B; Lim, DD; Meacham, RB; Rove, KO; Wilson, SS, 2011) |
| "To study the differential effects of bacillus Calmette-Guérin (BCG) and mitomycin C (MMC) intravesical therapy on the false-positive rate of PDD of bladder cancer." | 3.76 | Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. ( Bosch, JL; Draga, RO; Grimbergen, MC; Jonges, TN; Kok, ET; van Swol, CF, 2010) |
| "The human bladder cancer cell lines EJ28 and 5637 were transiently transfected with 3 antiVEGF AS-ODNs, followed by incubation with 3 doses of mitomycin C, gemcitabine or cisplatin CT." | 3.73 | Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin. ( Förster, Y; Fuessel, S; Kotzsch, M; Kraemer, K; Krause, S; Meye, A; Schmidt, U; Schwenzer, B; Wirth, MP, 2005) |
| "Transurethral resection followed by instillation of chemotherapeutic agents such as mitomycin is considered as standard therapy in recurrent superficial bladder cancer." | 3.73 | Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin. ( Fechner, G; Müller, SC; Pocha, K; Schmidt, D, 2006) |
| "The enhancing effects of Smac gene on the mitomycin C-induced apoptosis of the bladder cancer cell line T24 were investigated." | 3.73 | Smac/DIABLO promotes mitomycin C-induced apoptosis of bladder cancer T24 cells. ( Fuqing, Z; Tong, Q; Wang, L; Zheng, L, 2006) |
| " A reduction in urinary IL-8 levels after treatment with bacille Calmette-Guérin or mitomycin C may reflect a decrease in bladder cancer cells and/or in other cells that produce IL-8." | 3.72 | Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. ( Hausladen, DA; Sheryka, E; Weiss, RM; Wheeler, MA, 2003) |
| "Treatment of the T24 human bladder cancer cell line with anti-Fas mAb in combination with 5-fluorouracil, mitomycin C or methotrexate did not overcome resistance to these agents." | 3.70 | Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). ( Bonavida, B; Mizutani, Y; Yoshida, O, 1998) |
| "To compare the tumoricidal efficacy of meglumine gamma-linolenic acid (MeGLA), mitomycin C, epirubicin and water on two urothelial cell lines, and to establish the effect of serum protein levels derived from bladder cancer resection craters on the action of these agents." | 3.70 | Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent? ( Birch, BR; Cooper, AJ; Foley, SJ; Jennings, AM; Solomon, LZ, 1998) |
| "Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989." | 3.69 | Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Viganò, L, 1994) |
| "Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C." | 3.69 | Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy. ( Anderson, PJ; Frost, DB; Kagan, AR; Latino, F; Peddada, AV; Rao, AR; Shah, KH; Smith, DE, 1994) |
| "We evaluated the DNA cytophotometry in 446 bladder washing samples from 64 patients under mitomycin C after superficial bladder cancer during an observation period of up to 5 years." | 3.69 | Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy. ( Foeger, A; Maier, U; Marberger, M; Simak, R; Susani, M; Wiener, H; Zhang, ZF, 1996) |
| " Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along with its mitomycin C-resistant counterpart J82/MMC." | 3.69 | Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. ( Allman, R; Datta, SN; Loh, C; Mason, M; Matthews, PN, 1997) |
| "Bladder wall calcification is a rare complication of intravesical therapy of superficial bladder cancer with Mitomycin C." | 3.68 | Incrusted cystitis after intravesical mitomycin C treatment. ( Algado, M; Botella, R; Llopis, M; Moreno, J, 1993) |
| "The effect of intravesical instillation of 200,000 IU hyaluronidase in addition to mitomycin C as chemoprophylaxis of superficial bladder cancer was evaluated." | 3.68 | Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. ( Höbarth, K; Maier, U; Marberger, M, 1992) |
| "At the Institute of Urology, University of Padova, 125 patients with multifocal superficial bladder cancer underwent treatment with intravesical Mitomycin C (MMC; 1 weekly instillation of 40 mg for 8 consecutive weeks) between January 1982 and December 1988." | 3.68 | Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results. ( Bassi, P; Drago-Ferrante, GL; Garbeglio, A; Maruzzi, D; Meneghini, A; Milani, C; Pagano, F; Piazza, N; Zattoni, F, 1992) |
| "A chemosensitivity test was carried out on superficial bladder cancers using the trypan blue dye exclusion assay for the purpose of screening chemosensitive drugs for intravesical chemotherapy." | 3.68 | [Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy]. ( Irisawa, C; Koseki, K; Shiraiwa, Y, 1991) |
| "A total of 20 patients received intravesical bacillus Calmette-Guerin (BCG) or mitomycin C for the treatment of carcinoma in situ following previous pelvic radiation therapy." | 3.68 | Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. ( Pisters, LL; Tykochinsky, G; Wajsman, Z, 1991) |
| "Although intravesical mitomycin C (MMC) is effective in the treatment of superficial bladder cancer, its expense is a major factor limiting its use." | 3.67 | The stability and antitumor activity of recycled (intravesical) mitomycin C. ( Buice, RG; Hopkins, SC; Matheny, R; Soloway, MS, 1984) |
| "Mitomycin C is an active drug in the treatment of superficial bladder cancer." | 3.67 | Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors. ( Block, A; Dhafir, RA; Dragone, N; MacDonald, S; Pfeffer, M; Pontes, JE; Wajsman, Z, 1984) |
| "The use of mitomycin C, an effective agent in the intravesical treatment of superficial bladder cancer, is limited by its high cost." | 3.67 | Mitomycin C reused: an in vitro cost-effectiveness study. ( Carroll, PR; Dombrovskis, S; Kim, MJ; Williams, RD, 1984) |
| "Calcification of the bladder wall associated with intravesical mitomycin C for the treatment of superficial bladder cancer is a rare complication." | 3.67 | Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. ( Badalament, RA; Drago, JR; Drago, PC; Lucas, J, 1989) |
| "Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus." | 3.67 | Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986) |
| "Of 299 patients who presented with superficial bladder cancer (Ta, T1), 60 were treated by intravesical chemotherapy (Epodyl, methotrexate or mitomycin C)." | 3.67 | Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. ( Chisholm, GD; Elton, RA; Hargreave, TB; Newsam, JE; Smith, G, 1986) |
| "Three cases are presented in which eosinophilic cystitis developed when patients who were known to have superficial bladder cancer were treated with instillations of the alkylating agent Mitomycin C." | 3.67 | Allergy to mitomycin C complicating topical administration for urothelial cancer. ( Grigor, KM; Inglis, JA; Tolley, DA, 1987) |
| "A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer." | 3.67 | Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. ( Soloway, MS, 1985) |
| " The technique of cauterization and implantation of tumor cells was performed in C3H/He mice to simulate the early stage of bladder cancer to evaluate a regimen of intravesical mitomycin C followed by the systemic immunopotentiator, levamisole." | 3.66 | Chemoimmunotherapy of implanted murine bladder cancer. ( Akaza, H; Crabtree, WN; Matheny, RB; Soloway, MS, 1983) |
| "Twenty-three patients with histologically proven superficial bladder cancer (Tis, Ta, T1) were treated with intravesical instillations of Mitomycin C at a dose of 20 mg in 20 ml of water 3 times weekly for 21 instillations." | 3.66 | A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. ( Green, DF; Harrison, GS; Newling, DW; Richards, B; Robinson, MR; Smith, PH, 1983) |
| " Acute toxicity was assessed (Common Terminology Criteria for Adverse Events) weekly during radiotherapy and at 10 weeks after the start of treatment." | 3.30 | Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. ( Alonzi, R; Birtle, A; Cheung, KC; Choudhury, A; Foroudi, F; Gribble, H; Griffin, C; Hafeez, S; Hall, E; Henry, A; Hilman, S; Hindson, B; Huddart, R; Lewis, R; McLaren, DB; McNair, H; Muthukumar, D; Nikapota, A; Olorunfemi, A; Omar, A; Parikh, O; Philipps, L; Rimmer, Y; Syndikus, I; Tolentino, A; Varughese, M; Vassallo-Bonner, C; Webster, A, 2023) |
| " Protocol variability and dosage differences limit statistical interpretation." | 2.72 | Nephron-sparing management of upper tract urothelial carcinoma. ( Farrow, JM; Gryzinski, GM; Kern, SQ; Sundaram, CP, 2021) |
| "Bladder cancer is mostly superficial at first diagnosis." | 2.72 | Intravesical adjuvant therapy using mitomycin C. ( Bhuiyan, ZH; Islam, MA; Shameem, IA, 2006) |
| "Of 148 newly diagnosed patients with T1 bladder cancer 142 were prospectively randomized in 2 groups between January 2001 and January 2005." | 2.72 | The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. ( Divrik, RT; Ozen, H; Yildirim, U; Zorlu, F, 2006) |
| "Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall." | 2.71 | Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. ( Colombo, R; Gofrit, ON; Leib, Z; Naspro, R; Nativ, O; Pode, D; Shapiro, A; Sidi, A; van der Heijden, AG; Witjes, JA, 2004) |
| "A recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract is not rarely observed." | 2.70 | Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. ( Ariyoshi, A; Fujisawa, Y; Kumazawa, J; Morita, I; Naito, S; Omoto, T; Osada, Y; Sakamoto, N; Yamashita, H, 2001) |
| "The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone." | 2.70 | A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Moffitt, DD; Peake, D; Wallace, DM, 2001) |
| "The treatment of bladder cancer is one of the most active areas of clinical cancer research." | 2.66 | Approaches to the treatment of bladder cancer at Stanford. ( Torti, FM, 1987) |
| "Mitomycin C is an antitumor alkylating antibiotic agent that inhibits DNA synthesis extensively used as intravesical chemotherapy agent in the adjuvant treatment of urothelial carcinoma." | 2.58 | [Immediate post TURBT MMC instillation.] ( Domínguez-Escrig, JL, 2018) |
| "As our molecular understanding of bladder cancer continues to advance, more and more novel agents are entering clinical trials across the spectrum of bladder cancer stages." | 2.58 | Current Clinical Trials in Non-muscle Invasive Bladder Cancer. ( Batista da Costa, J; Black, PC; Mannas, M; Nykopp, TK, 2018) |
| "There was no disease progression in either treatment arm at three months' follow-up." | 2.55 | Intravesical electromotive drug administration for non-muscle invasive bladder cancer. ( Dahm, P; Gudeloglu, A; Jung, JH; Kiziloz, H; Konety, BR; Kuntz, GM; Miller, A, 2017) |
| "Non-muscle-invasive bladder cancer is characterized by frequent recurrences requiring repeated transurethral resections and carries a risk of progression to muscle-invasive disease." | 2.49 | Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC. ( Dekel, Y; Freifeld, Y; Stein, A, 2013) |
| "Close to 75% of all bladder tumors are confined to the urothelium (stage Ta, or carcinoma in situ), and nearly 30% of papillary tumors invade the lamina propria (stage T1)." | 2.41 | Intravesical therapy for superficial bladder cancer. ( Baselli, EC; Greenberg, RE, 2000) |
| "We present an additional case of rectal squamous cell carcinoma (SCC) complicating chronic ulcerative colitis in a 33-year-old woman who had the disease for 15 years." | 2.39 | Squamous cell carcinoma complicating idiopathic inflammatory bowel disease. ( Butler, B; Doerr, R; Kulaylat, MN; Satchidanand, SK; Singh, A, 1995) |
| "More than 90 percent of bladder cancers are transitional cell carcinoma (TCC)." | 2.38 | Managing superficial bladder cancer: an overview. ( Soloway, MS, 1992) |
| " Different dosage schedules and methods require further study." | 2.38 | Intravesical chemotherapy. Treatment selection, techniques, and results. ( Richie, JP, 1992) |
| "7." | 2.38 | Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. ( Jordan, AM; Murphy, WM; Soloway, MS, 1989) |
| "Management of the superficial bladder cancer patient consists of two complementary but separate therapeutic goals: treatment of the existing tumor(s) and prevention of tumor recurrence." | 2.37 | The biology and treatment of superficial bladder cancer. ( Lum, BL; Torti, FM, 1984) |
| " Ureteral stenosis and other adverse events were abstracted from the medical records." | 1.91 | Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. ( Bjurlin, M; Dickstein, R; Eisner, B; Feldman, A; Ghodoussipour, S; Humphreys, M; Jacob, J; Kaimakliotis, H; Labbate, C; Linehan, J; Lotan, Y; Matin, SF; Murray, K; Nieder, A; O'Donnell, M; Quek, M; Rose, K; Sexton, W; Tachibana, I; Woldu, S, 2023) |
| "A group of patients with urothelial bladder cancer, presenting for the first time for definitive treatment, were prospectively enrolled from 2013 to 2017." | 1.72 | Demographics, pathological characteristics and survival in urothelial bladder cancer in a cohort of Sri Lankan patients. ( Abeygunasekara, A; Dissanayake, V; Ediriweera, D; Goonewardena, S; Jayasekara, R; Lokuhetty, D; Malalasekera, AP; Perera, N; Wettasinghe, K, 2022) |
| "Thirty‑six C57BL/6J mice bearing bladder cancer were randomly divided into six treatment groups as follows: control, BCG, MMC, ADM, MMC‑BCG and ADM‑BCG." | 1.51 | Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment. ( Fujimoto, K; Gotoh, D; Hori, S; Iida, K; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, K; Onishi, S; Tanaka, N; Tatsumi, Y, 2019) |
| "The treatment of non muscle-invasive bladder cancer (NMIBC) encompasses a range of different procedures." | 1.46 | Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy). ( Bassi, PF; De Pascalis, I; Emilio, S; Larocca, LM; Lopez-Beltran, A; Marques, RC; Pierconti, F; Straccia, P; Volavsek, M, 2017) |
| "Pre- and post-treatment staging of anal cancer are often inaccurate." | 1.38 | Role of positron emission tomography-computed tomography in the management of anal cancer. ( Baccega, M; Bellò, M; Cassoni, P; Cravero, F; Filippini, C; Fora, G; Lesca, A; Milanesi, E; Mistrangelo, M; Morino, M; Munoz, FH; Pelosi, E; Racca, P; Ricardi, U; Skanjeti, A, 2012) |
| "RT112 bladder cancer cells (Catalog No." | 1.35 | Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure. ( Birare, N; Cooper, AJ; Lwaleed, BA, 2009) |
| "T739 mice were randomly divided into 8 groups after subcutaneous inoculation of bladder carcinoma cells, the control group (A); two mitomycin C (MMC) group, treated with MMC of routine dosage (B) and low-dosage (C) respectively; three SJZD groups, treated with SJZD of high (D), medium (E) and low-dosage (F) respectively; and two combined treatment groups, treated with SJZD of high-dosage + MMC of routine dosage(G) and SJZD of high-dosage + MMC of low-dosage(H)." | 1.33 | [Toxicity attenuation and efficacy potentiation effects of sijunzi decoction on bladder carcinoma treated by chemotherapy in mice]. ( Li, CG; Li, ML; Shu, XH, 2005) |
| "Mitomycin (10 mg/m) was instilled in 9 rats and saline was used in the control group." | 1.33 | Intraperitoneal chemotherapy for the prevention of transitional cell carcinoma implantation. ( Abaza, R; Keck, RW; Selman, SH, 2006) |
| "In patients with superficial bladder cancer, the occurrence of primary carcinoma in situ was significantly greater in patients with the AA genotype compared with those with the GA or GG genotypes (P = 0." | 1.32 | Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. ( Habuchi, T; Higashi, S; Ito, M; Kamoto, T; Nishiyama, H; Ogawa, O; Tsuchiya, N; Wang, L; Watanabe, J, 2004) |
| "In phase II trials in superficial bladder cancer, marker lesions have been used to test the ablative activity of intravesical chemo- or immunotherapy." | 1.31 | Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. ( Bono, AV; Brausi, M; de Balincourt, C; Hall, R; Mack, D; Oosterlinck, W; Sylvester, R, 2001) |
| "Mitomycin C has limited systemic absorption when given intravesically because of its high molecular weight." | 1.30 | Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. ( Bagley, DH; Keeley, FX, 1997) |
| "Human solid tumor histocultures represent a clinically relevant experimental system for pharmacodynamic study." | 1.30 | Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. ( Au, JL; Weaver, JR; Wientjes, MG, 1999) |
| "Mitomycin C was administered initially and mitoxantrone was administered following the same schedule if disease recurred during followup." | 1.29 | Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. ( Carmignani, G; Maffezzini, M; Raber, M; Simonato, A; Zanon, M, 1996) |
| "A human bladder cancer cell line resistant to adriamycin (ADM), T24/ADM9 has been established in vitro by exposing T24 parent cells to progressively higher concentrations of the drug over a period of 12 months." | 1.29 | Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. ( Hasegawa, S; Koga, H; Kotoh, S; Kumazawa, J; Kuwano, M; Naito, S; Yokomizo, A, 1995) |
| "Trans-urethral resection of the bladder cancer was performed in 8 patients, supported in two cases by immunotherapy with B." | 1.29 | [pT1G3 bladder carcinoma: our experience]. ( Bernardini, P; D'Addezio, F; Del Nero, A; Dell'Orto, P; Mangiarotti, B; Pisani, E; Trinchieri, A, 1996) |
| "mitomycin C after pretreatment with interferon alpha showed a dramatic decrease in cell proliferation (from 98." | 1.29 | Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C. ( Kinne, RK; Okamoto, E; Sökeland, J, 1996) |
| " The goal of the present study was to determine if the efficacy of intravesical MMC therapy in patients treated for superficial bladder cancer can be enhanced by using acidified dosing solutions." | 1.29 | Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. ( Au, JL; Schmittgen, T; Yen, WC, 1996) |
| "Eosinophilic cystitis is an unusual form of cystitis which is characterized by irritative voiding symptoms and haematuria." | 1.29 | Eosinophilic cystitis induced by mitomycin-C. ( Apaydin, E; Gürsan, A; Kandiloğlu, G; Ozyurt, C; Ulker, V, 1996) |
| " The success of treatment seems out of question on dosage but with the continuation of the instillation program." | 1.28 | Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma. ( Wu, JJ; Yin, ZL; Zhu, JN, 1992) |
| " PDT combined with either adriamycin, MMC or BCG, produced a greater retardation in the growth of the MBT-2 tumor than monotherapy with adriamycin, MMC, BCG or PDT." | 1.28 | Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. ( Cho, YH; Smith, JA; Straight, RC, 1992) |
| " Combination with mitomycin C or interferon-alpha-2b potentiated the cytostatic effect." | 1.28 | Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. ( Alfthan, O; Jauhiainen, K; Kaasinen, E; Lähde, M; Nurmi, M; Rajala, P; Rintala, E, 1992) |
| "One hundred three patients with bladder cancer underwent balloon-occluded arterial infusion." | 1.28 | [Balloon-occluded arterial infusion as chemotherapy in bladder cancer--long-term results]. ( Kawabata, M; Mitsuzane, K; Nomura, S; Sato, M; Terada, M; Yamada, R, 1990) |
| "Mitomycin C has proved to be useful as prophylaxis against superficial bladder tumor recurrences." | 1.27 | Prostatic recurrences in the management of superficial bladder tumors. ( Bondhus, MJ; Chaikin, L; Lockhart, JL; Politano, VA, 1983) |
| "Most superficial bladder tumors are best treated by transurethral resection." | 1.27 | Severely contracted bladder following intravesical mitomycin C therapy. ( Englander, L; Huben, RP; McGill, W; Pontes, JE; Wajsman, Z, 1983) |
| "Mitomycin C was administered in one course of 10 daily doses of 40 mg, starting 24 to 48 hours after TUR." | 1.27 | Intravesical instillation of mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder. ( Bendimerad, O; Bouvier, R; Devonec, M; Dubernard, JM; Gelet, A; Sarkissian, J, 1983) |
| "The rate of recurring bladder tumors decreased after instillation therapy." | 1.27 | [Experimental and clinical studies on intravesical instillation therapy for bladder cancer]. ( Imai, K; Kaburagi, Y; Miki, M; Yamanaka, H, 1983) |
| "Urine from patients with bladder cancer before treatment had osmolalities in the range 187 to 852 mOsm." | 1.27 | Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity. ( Groos, E; Masters, JR, 1986) |
| " During the first week of radiotherapy, 5-fluorouracil (1000 mg/m2 daily for four days by continuous infusion), and mitomycin (10 mg/m2 on day 1) were administered; four weeks later, a second cycle at the same dosage followed." | 1.27 | [Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy]. ( Dunst, J; Reichard, U; Sauer, R; Wolf, N, 1987) |
| "Patients with multiple bladder tumors, bladder tumors inaccessible to endoscopic resection, or lesions too extensive to completely resect, or with medial contraindications for endoscopic resection procedures, were included in these studies." | 1.27 | Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor. ( Gonder, M; Hu, KN; Khan, AS; Kim, A; Soroff, H, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 104 (27.30) | 18.7374 |
| 1990's | 104 (27.30) | 18.2507 |
| 2000's | 78 (20.47) | 29.6817 |
| 2010's | 66 (17.32) | 24.3611 |
| 2020's | 29 (7.61) | 2.80 |
| Authors | Studies |
|---|---|
| Rosen, GH | 1 |
| Nallani, A | 1 |
| Muzzey, C | 1 |
| Murray, KS | 6 |
| Song, Y | 1 |
| Du, Y | 1 |
| Qin, C | 1 |
| Xu, T | 1 |
| Kim, SH | 1 |
| Lerner, SP | 2 |
| Daryanto, B | 1 |
| Purnomo, AF | 1 |
| Seputra, KP | 1 |
| Budaya, TN | 1 |
| Hegmann, L | 1 |
| Sturm, S | 1 |
| Niegisch, G | 1 |
| Windolf, J | 1 |
| Suschek, CV | 1 |
| Rose, KM | 3 |
| Narang, G | 1 |
| Rosen, G | 1 |
| Labatte, C | 1 |
| Dumitrascu, CI | 1 |
| Campagna, J | 1 |
| Yu, A | 1 |
| Manley, BJ | 1 |
| Spiess, PE | 1 |
| Li, R | 1 |
| Adibi, M | 1 |
| Sexton, WJ | 2 |
| Humphreys, MR | 3 |
| Woldu, SL | 3 |
| Labbate, C | 6 |
| Rose, K | 5 |
| Sexton, W | 5 |
| Tachibana, I | 5 |
| Kaimakliotis, H | 5 |
| Jacob, J | 6 |
| Dickstein, R | 6 |
| Linehan, J | 7 |
| Nieder, A | 5 |
| Bjurlin, MA | 3 |
| Humphreys, M | 5 |
| Ghodoussipour, S | 5 |
| Quek, ML | 3 |
| O'Donnell, M | 5 |
| Eisner, BH | 4 |
| Feldman, AS | 4 |
| Matin, SF | 9 |
| Lotan, Y | 9 |
| Woldu, S | 4 |
| Murray, K | 2 |
| Bjurlin, M | 2 |
| Quek, M | 2 |
| Eisner, B | 1 |
| Feldman, A | 2 |
| van Wijngaarden, C | 1 |
| Bus, MTJ | 1 |
| Ruiter, AEC | 1 |
| Lagerveld, BW | 1 |
| Soria, F | 2 |
| Delacruz, JE | 1 |
| Aznar-Cervantes, SD | 1 |
| Aranda, J | 1 |
| Martínez-Pla, L | 1 |
| Cepeda, M | 1 |
| Pérez-Lanzac, A | 1 |
| Bueno, G | 1 |
| Sánchez-Margallo, FM | 1 |
| Halstuch, D | 1 |
| Lotan, P | 1 |
| Karchever, I | 1 |
| Rubinshtein, D | 1 |
| Kedar, D | 2 |
| Baniel, J | 3 |
| Golan, S | 1 |
| Song, S | 1 |
| Smith, A | 1 |
| Hu, B | 2 |
| Asero, V | 1 |
| Scornajenghi, CM | 1 |
| Krajewski, W | 1 |
| Szydełko, T | 1 |
| Malkiewicz, B | 1 |
| Nowak, Ł | 1 |
| Gallioli, A | 2 |
| Basran, S | 1 |
| Chung, BI | 1 |
| Del Giudice, F | 1 |
| Huddart, R | 2 |
| Hafeez, S | 1 |
| Omar, A | 1 |
| Alonzi, R | 1 |
| Birtle, A | 2 |
| Cheung, KC | 1 |
| Choudhury, A | 1 |
| Foroudi, F | 1 |
| Gribble, H | 1 |
| Henry, A | 1 |
| Hilman, S | 1 |
| Hindson, B | 1 |
| Lewis, R | 2 |
| Muthukumar, D | 1 |
| McLaren, DB | 1 |
| McNair, H | 1 |
| Nikapota, A | 1 |
| Olorunfemi, A | 1 |
| Parikh, O | 1 |
| Philipps, L | 1 |
| Rimmer, Y | 1 |
| Syndikus, I | 2 |
| Tolentino, A | 1 |
| Varughese, M | 1 |
| Vassallo-Bonner, C | 1 |
| Webster, A | 1 |
| Griffin, C | 1 |
| Hall, E | 3 |
| Kaimakliotis, HZ | 2 |
| Akbulut, F | 1 |
| Pazir, Y | 1 |
| Esmeray, A | 1 |
| Erbin, A | 1 |
| Ozgor, F | 1 |
| Sarilar, O | 1 |
| Malalasekera, AP | 1 |
| Ediriweera, D | 1 |
| Goonewardena, S | 1 |
| Perera, N | 1 |
| Abeygunasekara, A | 1 |
| Jayasekara, R | 1 |
| Wettasinghe, K | 1 |
| Dissanayake, V | 1 |
| Lokuhetty, D | 1 |
| Faraj, K | 1 |
| Chang, YH | 1 |
| Habermann, EB | 1 |
| Etzioni, DA | 1 |
| Blodgett, G | 1 |
| Castle, EP | 1 |
| Tyson Ii, MD | 1 |
| Schmidt, S | 1 |
| Kunath, F | 1 |
| Coles, B | 3 |
| Draeger, DL | 1 |
| Krabbe, LM | 1 |
| Dersch, R | 1 |
| Kilian, S | 1 |
| Jensen, K | 1 |
| Dahm, P | 2 |
| Meerpohl, JJ | 1 |
| Okeke, Z | 2 |
| Rai, A | 1 |
| Alsyouf, M | 1 |
| Pierorazio, P | 1 |
| Groegler, J | 1 |
| Dreicer, R | 1 |
| Territo, A | 1 |
| Breda, A | 1 |
| Freifeld, Y | 2 |
| Ghandour, R | 1 |
| Singla, N | 1 |
| Bagrodia, A | 1 |
| Rapoport, LM | 1 |
| Gazimiev, M | 1 |
| Delafuente, K | 1 |
| Kulangara, R | 1 |
| Robyak, H | 1 |
| Petros, FG | 1 |
| Raman, JD | 3 |
| Margulis, V | 1 |
| Pierconti, F | 2 |
| Martini, M | 1 |
| Fiorentino, V | 1 |
| Cenci, T | 1 |
| Capodimonti, S | 1 |
| Straccia, P | 2 |
| Sacco, E | 1 |
| Pugliese, D | 1 |
| Cindolo, L | 1 |
| Larocca, LM | 2 |
| Bassi, PF | 2 |
| Porta, C | 1 |
| Giannatempo, P | 1 |
| Rizzo, M | 1 |
| Lucarelli, G | 1 |
| Ditonno, P | 1 |
| Battaglia, M | 1 |
| Ourfali, S | 1 |
| Colombel, M | 1 |
| Schoenberg, M | 1 |
| Seltzer, E | 1 |
| Thacker, K | 1 |
| Smith, AB | 1 |
| Farrow, JM | 1 |
| Kern, SQ | 1 |
| Gryzinski, GM | 1 |
| Sundaram, CP | 1 |
| Metcalfe, M | 1 |
| Wagenheim, G | 2 |
| Xiao, L | 2 |
| Papadopoulos, J | 2 |
| Navai, N | 2 |
| Davis, JW | 2 |
| Karam, JA | 3 |
| Kamat, AM | 2 |
| Wood, CG | 2 |
| Dinney, CP | 2 |
| Somani, BK | 1 |
| Hodgkinson, L | 1 |
| Emilio, S | 1 |
| De Pascalis, I | 1 |
| Marques, RC | 1 |
| Volavsek, M | 1 |
| Lopez-Beltran, A | 1 |
| Jung, JH | 1 |
| Gudeloglu, A | 1 |
| Kiziloz, H | 1 |
| Kuntz, GM | 1 |
| Miller, A | 1 |
| Konety, BR | 1 |
| Wilson, SS | 2 |
| Crawford, ED | 2 |
| Unda-Urzaiz, M | 1 |
| Fernandez-Gomez, JM | 1 |
| Cozar-Olmo, JM | 1 |
| Juárez, A | 1 |
| Palou, J | 4 |
| Martínez-Piñeiro, L | 1 |
| Xylinas, E | 2 |
| Kent, M | 1 |
| Dabi, Y | 1 |
| Rieken, M | 2 |
| Kluth, LA | 1 |
| Al Hussein Al Awamlh, B | 1 |
| Ouzaid, I | 1 |
| Pycha, A | 2 |
| Comploj, E | 1 |
| Svatek, RS | 2 |
| Karakiewicz, PI | 2 |
| Holmang, S | 2 |
| Shariat, SF | 4 |
| Tselis, N | 1 |
| Prott, FJ | 1 |
| Ott, O | 1 |
| Weiss, C | 1 |
| Rödel, C | 2 |
| Domínguez-Escrig, JL | 1 |
| Tapiero, S | 1 |
| Helfand, A | 1 |
| Yossepowitch, O | 1 |
| Nadu, A | 1 |
| Lifshitz, D | 1 |
| Margel, D | 1 |
| Balasubramanian, A | 1 |
| Metcalfe, MJ | 1 |
| Ubrig, B | 1 |
| Roth, S | 1 |
| Boy, A | 1 |
| Kelly, JD | 3 |
| Tan, WS | 1 |
| Porta, N | 1 |
| Mostafid, H | 1 |
| Protheroe, A | 1 |
| Bogle, R | 1 |
| Blazeby, J | 1 |
| Palmer, A | 1 |
| Cresswell, J | 1 |
| Johnson, M | 1 |
| Brough, R | 1 |
| Madaan, S | 1 |
| Andrews, S | 1 |
| Cruickshank, C | 1 |
| Burnett, S | 1 |
| Maynard, L | 1 |
| Nykopp, TK | 1 |
| Batista da Costa, J | 1 |
| Mannas, M | 1 |
| Black, PC | 1 |
| Hori, S | 1 |
| Miyake, M | 1 |
| Tatsumi, Y | 1 |
| Morizawa, Y | 1 |
| Nakai, Y | 1 |
| Onishi, S | 1 |
| Onishi, K | 1 |
| Iida, K | 1 |
| Gotoh, D | 1 |
| Itami, Y | 1 |
| Tanaka, N | 1 |
| Fujimoto, K | 1 |
| Arshad, Z | 1 |
| Zaidi, SZ | 1 |
| Zilli, T | 1 |
| Betz, M | 1 |
| Bieri, S | 1 |
| Ris, F | 1 |
| Roche, B | 1 |
| Roth, AD | 1 |
| Allal, AS | 1 |
| Huddart, RA | 1 |
| Hussain, SA | 3 |
| Jenkins, P | 1 |
| Rawlings, C | 1 |
| Tremlett, J | 1 |
| Crundwell, M | 1 |
| Adab, FA | 1 |
| Sheehan, D | 1 |
| Hendron, C | 1 |
| Waters, R | 1 |
| James, ND | 3 |
| Gunderson, LL | 1 |
| Moughan, J | 1 |
| Ajani, JA | 1 |
| Pedersen, JE | 1 |
| Winter, KA | 1 |
| Benson, AB | 1 |
| Thomas, CR | 1 |
| Mayer, RJ | 1 |
| Haddock, MG | 2 |
| Rich, TA | 1 |
| Willett, CG | 2 |
| Elmamoun, MH | 1 |
| Christmas, TJ | 1 |
| Woodhouse, CR | 1 |
| Arentsen, HC | 2 |
| Falke, J | 2 |
| Høgset, A | 1 |
| Oosterwijk, E | 2 |
| Alfred Witjes, J | 2 |
| Milla, P | 1 |
| Fiorito, C | 1 |
| Arpicco, S | 1 |
| Cattel, L | 1 |
| Gontero, P | 1 |
| Molina Escudero, R | 1 |
| Alvarez Ardura, M | 1 |
| Ripalda Ferretti, E | 1 |
| Crespo Martínez, L | 1 |
| González Avila, N | 1 |
| Dorado Valentín, M | 1 |
| Páez Borda, A | 1 |
| Zhao, XR | 1 |
| Morales, EE | 1 |
| Jha, MK | 1 |
| Tseng, TY | 1 |
| Hugen, CM | 1 |
| Hurez, V | 1 |
| Hernandez, J | 1 |
| Curiel, TJ | 1 |
| Arends, TJ | 1 |
| Lammers, RJ | 1 |
| Somford, DM | 1 |
| Hendriks, JC | 1 |
| de Weijert, MC | 1 |
| van der Heijden, AG | 4 |
| Cui, M | 1 |
| Au, JL | 7 |
| Wientjes, MG | 5 |
| O'Donnell, MA | 1 |
| Loughlin, KR | 1 |
| Lu, Z | 1 |
| Seisen, T | 1 |
| Colin, P | 1 |
| Rouprêt, M | 6 |
| Ekin, RG | 1 |
| Akarken, I | 1 |
| Cakmak, O | 1 |
| Tarhan, H | 1 |
| Celik, O | 1 |
| Ilbey, YO | 1 |
| Divrik, RT | 2 |
| Zorlu, F | 2 |
| Gakis, G | 1 |
| Morgan, TM | 1 |
| Daneshmand, S | 1 |
| Keegan, KA | 1 |
| Todenhöfer, T | 1 |
| Mischinger, J | 1 |
| Schubert, T | 1 |
| Zaid, HB | 1 |
| Hrbacek, J | 1 |
| Ali-El-Dein, B | 2 |
| Clayman, RH | 1 |
| Galland, S | 1 |
| Olugbade, K | 1 |
| Rink, M | 2 |
| Fritsche, HM | 1 |
| Burger, M | 2 |
| Chang, SS | 2 |
| Babjuk, M | 4 |
| Thalmann, GN | 1 |
| Stenzl, A | 1 |
| Efstathiou, JA | 1 |
| Sylvester, RJ | 2 |
| Oosterlinck, W | 6 |
| Sydes, MR | 1 |
| Gudjonsson, S | 1 |
| De Nunzio, C | 1 |
| Okamura, K | 1 |
| Kaasinen, E | 4 |
| Solsona, E | 1 |
| Tatar, CA | 1 |
| Inman, BA | 1 |
| N'Dow, J | 1 |
| Oddens, JR | 1 |
| Compérat, E | 1 |
| Zigeuner, R | 2 |
| Cowan, NC | 1 |
| Böhle, A | 3 |
| Van Rhijn, BW | 1 |
| Shibing, Y | 1 |
| Qiang, W | 1 |
| Shelley, M | 1 |
| Court, JB | 2 |
| Kynaston, HG | 1 |
| Wilt, TJ | 2 |
| Mason, M | 3 |
| Motamedinia, P | 1 |
| Keheila, M | 1 |
| Leavitt, DA | 1 |
| Rastinehad, AR | 2 |
| Smith, AD | 3 |
| Ojha, R | 1 |
| Jha, V | 1 |
| Singh, SK | 1 |
| Mbeutcha, A | 1 |
| Seitz, C | 1 |
| Lucca, I | 1 |
| Mathieu, R | 1 |
| Briganti, A | 1 |
| Klatte, T | 1 |
| Donin, NM | 1 |
| Duarte, S | 1 |
| Lenis, AT | 1 |
| Caliliw, R | 1 |
| Torres, C | 1 |
| Smithson, A | 1 |
| Strauss-Ayali, D | 1 |
| Agmon-Gerstein, Y | 1 |
| Malchi, N | 1 |
| Said, J | 1 |
| Raman, SS | 1 |
| Holden, S | 1 |
| Pantuck, A | 1 |
| Belldegrun, AS | 1 |
| Chamie, K | 1 |
| Lu, DD | 1 |
| Boorjian, SA | 1 |
| Dangle, PP | 1 |
| Wang, WP | 1 |
| Pohar, KS | 1 |
| El-Ghobashy, S | 1 |
| El-Leithy, TR | 1 |
| Roshdy, MM | 1 |
| El-Ganzoury, HM | 1 |
| Jalón Monzón, A | 1 |
| Fernández Gómez, JM | 1 |
| Escaf Barmadah, S | 1 |
| Alvarez Múgica, M | 1 |
| Martín Benito, JL | 1 |
| Regadera Sejas, FJ | 1 |
| Abaza, R | 2 |
| Miocinovic, R | 1 |
| Keck, RW | 2 |
| Selman, SH | 2 |
| Lingnau, A | 1 |
| Miller, K | 1 |
| Steiner, U | 1 |
| Jentzmik, F | 1 |
| Weikert, S | 1 |
| Schostak, M | 1 |
| Cameo, MI | 1 |
| Lezcano, MA | 1 |
| Gil, D | 1 |
| Blas, M | 1 |
| Birare, N | 1 |
| Lwaleed, BA | 2 |
| Cooper, AJ | 3 |
| Draga, RO | 1 |
| Grimbergen, MC | 1 |
| Kok, ET | 1 |
| Jonges, TN | 1 |
| van Swol, CF | 1 |
| Bosch, JL | 1 |
| Addeo, R | 1 |
| Caraglia, M | 1 |
| Bellini, S | 1 |
| Abbruzzese, A | 1 |
| Vincenzi, B | 1 |
| Montella, L | 1 |
| Miragliuolo, A | 1 |
| Guarrasi, R | 1 |
| Lanna, M | 1 |
| Cennamo, G | 1 |
| Faiola, V | 1 |
| Del Prete, S | 1 |
| Wu, WJ | 1 |
| Ke, HL | 1 |
| Yang, YH | 1 |
| Li, CC | 1 |
| Chou, YH | 1 |
| Huang, CH | 1 |
| Nieder, AM | 1 |
| Guillotreau, J | 1 |
| Irani, J | 1 |
| Zerbib, M | 2 |
| Verma, A | 1 |
| Degrado, J | 1 |
| Hittelman, AB | 1 |
| Wheeler, MA | 3 |
| Weiss, RM | 3 |
| Mansoor, M | 1 |
| Ali, S | 1 |
| Fasihuddin, Q | 1 |
| Baloch, MU | 1 |
| Onishi, T | 1 |
| Sasaki, T | 1 |
| Hoshina, A | 1 |
| Yabana, T | 1 |
| Bhattacharyya, M | 1 |
| Powles, T | 1 |
| Mutsvangwa, K | 1 |
| Wilson, P | 1 |
| Oliver, T | 1 |
| Shamash, J | 1 |
| Badalato, GM | 1 |
| Hruby, G | 1 |
| Razmjoo, M | 1 |
| McKiernan, JM | 1 |
| Deb, AA | 1 |
| Rove, KO | 1 |
| Kumar, B | 1 |
| Koul, S | 1 |
| Lim, DD | 1 |
| Meacham, RB | 1 |
| Koul, HK | 1 |
| Boehle, A | 1 |
| Sylvester, R | 7 |
| Watson, CJ | 1 |
| O'Kane, H | 1 |
| Maxwell, P | 2 |
| Sharaf, O | 1 |
| Petak, I | 1 |
| Hyland, PL | 1 |
| O'Rouke, D | 1 |
| McKnight, J | 1 |
| Canning, P | 2 |
| Williamson, K | 1 |
| Zhang, CJ | 1 |
| Shen, ZJ | 1 |
| Pan, CW | 1 |
| Zhong, S | 1 |
| Li, T | 1 |
| Zhang, MG | 1 |
| Cutress, ML | 1 |
| Stewart, GD | 1 |
| Zakikhani, P | 1 |
| Phipps, S | 1 |
| Thomas, BG | 1 |
| Tolley, DA | 6 |
| Mistrangelo, M | 1 |
| Pelosi, E | 1 |
| Bellò, M | 1 |
| Ricardi, U | 1 |
| Milanesi, E | 1 |
| Cassoni, P | 1 |
| Baccega, M | 1 |
| Filippini, C | 1 |
| Racca, P | 1 |
| Lesca, A | 1 |
| Munoz, FH | 1 |
| Fora, G | 1 |
| Skanjeti, A | 1 |
| Cravero, F | 1 |
| Morino, M | 1 |
| Castillo, OA | 1 |
| Landerer, E | 1 |
| Feria-Flores, M | 1 |
| Vidal-Mora, I | 1 |
| Franco, C | 1 |
| Li, L | 1 |
| Li, B | 1 |
| Shao, J | 1 |
| Wang, X | 2 |
| Kachnic, LA | 1 |
| Winter, K | 1 |
| Myerson, RJ | 1 |
| Goodyear, MD | 1 |
| Willins, J | 1 |
| Esthappan, J | 1 |
| Rotman, M | 1 |
| Parikh, PJ | 1 |
| Safran, H | 1 |
| Dekel, Y | 2 |
| Stein, A | 1 |
| Smith, P | 1 |
| Mandel, J | 1 |
| Barlow, LJ | 1 |
| Benson, MC | 2 |
| Hara, I | 1 |
| Miyake, H | 1 |
| Takechi, Y | 1 |
| Eto, H | 1 |
| Gotoh, A | 1 |
| Fujisawa, M | 1 |
| Okada, H | 1 |
| Arakawa, S | 1 |
| Kamidono, S | 1 |
| Lynn, NN | 1 |
| Howe, MC | 1 |
| Hale, RJ | 1 |
| Collins, GN | 1 |
| O'Reilly, PH | 1 |
| Liu, J | 2 |
| Wang, Q | 1 |
| Sun, Y | 1 |
| Chen, XY | 1 |
| Kong, Q | 1 |
| Zhang, KL | 1 |
| Li, H | 1 |
| Hausladen, DA | 2 |
| Altieri, DC | 1 |
| Colberg, JW | 1 |
| Tong, M | 1 |
| Yu, LZ | 1 |
| Ding, Y | 1 |
| Liu, LB | 1 |
| Pan, BN | 1 |
| Na, YQ | 1 |
| Sheryka, E | 1 |
| Graf, R | 1 |
| Wust, P | 1 |
| Hildebrandt, B | 1 |
| Gögler, H | 1 |
| Ullrich, R | 1 |
| Herrmann, R | 1 |
| Riess, H | 1 |
| Felix, R | 1 |
| Di Stasi, SM | 2 |
| Giannantoni, A | 2 |
| Stephen, RL | 3 |
| Capelli, G | 2 |
| Navarra, P | 1 |
| Massoud, R | 1 |
| Vespasiani, G | 2 |
| Shelley, MD | 1 |
| Kynaston, H | 1 |
| Server Pastor, G | 1 |
| Rigabert Montiel, M | 1 |
| Bañón Pérez, V | 1 |
| Valdelvira Nadal, P | 1 |
| Cao Avellaneda, E | 1 |
| García Hernández, JA | 1 |
| Pérez Albacete, M | 1 |
| Rath-Wolfson, L | 1 |
| Moskovitz, B | 2 |
| Kugel, V | 1 |
| Koren, R | 1 |
| Kijima, T | 1 |
| Masuda, H | 1 |
| Suzuki, M | 1 |
| Okada, Y | 1 |
| Yano, M | 1 |
| Hyochi, N | 1 |
| Fujii, Y | 1 |
| Kawakami, S | 1 |
| Hayashi, T | 1 |
| Kobayashi, T | 1 |
| Kihara, K | 1 |
| Colombo, R | 6 |
| Da Pozzo, LF | 3 |
| Salonia, A | 2 |
| Rigatti, P | 5 |
| Leib, Z | 2 |
| Caldarera, E | 1 |
| Pavone-Macaluso, M | 1 |
| Lamm, DL | 1 |
| Peyromaure, M | 1 |
| Gofrit, ON | 1 |
| Shapiro, A | 1 |
| Pode, D | 1 |
| Sidi, A | 1 |
| Nativ, O | 1 |
| Witjes, JA | 7 |
| Naspro, R | 1 |
| Bock, PR | 1 |
| Stocken, DD | 1 |
| Peake, DR | 1 |
| Glaholm, JG | 2 |
| Zarkar, A | 1 |
| Wallace, DM | 3 |
| Piovesan, LF | 1 |
| Huguet, J | 1 |
| Salvador, J | 1 |
| Vicente, J | 1 |
| Villavicencio, H | 1 |
| Ito, M | 1 |
| Habuchi, T | 1 |
| Watanabe, J | 1 |
| Higashi, S | 1 |
| Nishiyama, H | 1 |
| Wang, L | 2 |
| Tsuchiya, N | 1 |
| Kamoto, T | 1 |
| Ogawa, O | 1 |
| O'Donoghue, JP | 1 |
| Crew, JP | 1 |
| Basu, S | 1 |
| Brown, JE | 1 |
| Flannigan, GM | 1 |
| Gill, JH | 1 |
| Loadman, PM | 1 |
| Martin, SW | 1 |
| Naylor, B | 1 |
| Puri, R | 1 |
| Scally, AJ | 1 |
| Seargent, JM | 1 |
| Shah, T | 1 |
| Phillips, RM | 1 |
| Fidalgo, A | 1 |
| Lobo, L | 1 |
| Verhaegh, G | 1 |
| Jansen, CF | 1 |
| Schalken, JA | 1 |
| Raviv, G | 1 |
| Pinthus, JH | 1 |
| Shefi, S | 1 |
| Mor, Y | 1 |
| Kaufman-Francis, K | 1 |
| Levron, J | 1 |
| Weissenberg, R | 1 |
| Ramon, J | 1 |
| Madgar, I | 1 |
| Li, CG | 1 |
| Li, ML | 1 |
| Shu, XH | 1 |
| Skyrme, RJ | 1 |
| French, AJ | 1 |
| Datta, SN | 2 |
| Allman, R | 2 |
| Mason, MD | 1 |
| Matthews, PN | 2 |
| Krause, S | 1 |
| Förster, Y | 1 |
| Kraemer, K | 1 |
| Fuessel, S | 1 |
| Kotzsch, M | 1 |
| Schmidt, U | 1 |
| Wirth, MP | 1 |
| Meye, A | 1 |
| Schwenzer, B | 1 |
| Mullerad, M | 1 |
| Bochner, BH | 2 |
| Adusumilli, PS | 1 |
| Bhargava, A | 1 |
| Kikuchi, E | 1 |
| Hui-Ni, C | 1 |
| Kattan, MW | 1 |
| Chou, TC | 1 |
| Fong, Y | 1 |
| Racioppi, M | 1 |
| Porreca, A | 1 |
| Foschi, N | 1 |
| Delicato, G | 1 |
| Destito, A | 1 |
| D'Addessi, A | 1 |
| Giurioli, A | 1 |
| Valenti, M | 1 |
| Zampa, G | 1 |
| Storti, L | 1 |
| Attisani, F | 1 |
| De Carolis, A | 1 |
| Trinchieri, A | 2 |
| Bonacina, P | 1 |
| Butti, A | 1 |
| Cappoli, S | 1 |
| Esposito, N | 1 |
| Invernizzi, S | 1 |
| Librizzi, A | 1 |
| Locatelli, G | 1 |
| Islam, MA | 1 |
| Bhuiyan, ZH | 1 |
| Shameem, IA | 1 |
| Yildirim, U | 1 |
| Ozen, H | 1 |
| Fechner, G | 1 |
| Pocha, K | 1 |
| Schmidt, D | 1 |
| Müller, SC | 1 |
| Kureshi, F | 1 |
| Kalaaji, AN | 1 |
| Halvorson, L | 1 |
| Pittelkow, MR | 1 |
| Davis, MD | 1 |
| Bolenz, C | 1 |
| Cao, Y | 2 |
| Arancibia, MF | 1 |
| Trojan, L | 1 |
| Alken, P | 1 |
| Michel, MS | 1 |
| Fuqing, Z | 1 |
| Zheng, L | 1 |
| Tong, Q | 1 |
| Segawa, N | 1 |
| Kotake, Y | 1 |
| Hamada, S | 1 |
| Takahara, K | 1 |
| Azuma, H | 1 |
| Katsuoka, Y | 1 |
| Tsuji, M | 1 |
| Friedrich, MG | 2 |
| Pichlmeier, U | 3 |
| Schwaibold, H | 3 |
| Conrad, S | 2 |
| Huland, H | 6 |
| Evans, CP | 1 |
| Hulsbergen-Van de Kaa, CA | 1 |
| Qiao, BM | 1 |
| Sun, G | 1 |
| Tang, Y | 1 |
| Chang, JW | 1 |
| Wang, WC | 1 |
| Ma, TX | 1 |
| Speers, AG | 1 |
| Featherstone, JM | 1 |
| Chen, F | 1 |
| Zhang, G | 1 |
| Payne, R | 1 |
| See, WA | 1 |
| Ashfaq, R | 1 |
| Sagalowsky, AI | 1 |
| Soler-Martínez, J | 1 |
| Vozmediano-Chicharro, R | 1 |
| Morales-Jiménez, P | 1 |
| Hernández-Alcaraz, D | 1 |
| Vivas-Vargas, E | 1 |
| Santos García-Vaquero, I | 1 |
| Baena-González, V | 1 |
| Kalsi, J | 1 |
| Harland, SJ | 1 |
| Feneley, MR | 1 |
| Ost, MC | 1 |
| Patel, KP | 1 |
| Chu, PY | 1 |
| Anderson, AE | 1 |
| Lee, BR | 1 |
| Isbarn, H | 1 |
| Budäus, L | 1 |
| Weisenthal, LM | 1 |
| Lalude, AO | 1 |
| Miller, JB | 1 |
| Uchibayashi, T | 1 |
| Paulson, DF | 1 |
| Kato, T | 1 |
| Salem, PA | 1 |
| Neild, VS | 1 |
| Sanderson, KV | 1 |
| Riddle, PR | 1 |
| Akaza, H | 1 |
| Crabtree, WN | 1 |
| Matheny, RB | 1 |
| Soloway, MS | 18 |
| Tannock, IF | 1 |
| Lockhart, JL | 1 |
| Chaikin, L | 1 |
| Bondhus, MJ | 1 |
| Politano, VA | 1 |
| Wajsman, Z | 3 |
| McGill, W | 1 |
| Englander, L | 1 |
| Huben, RP | 2 |
| Pontes, JE | 2 |
| Murphy, WM | 5 |
| Devonec, M | 1 |
| Bouvier, R | 1 |
| Sarkissian, J | 1 |
| Bendimerad, O | 1 |
| Gelet, A | 1 |
| Dubernard, JM | 1 |
| Thomas, SD | 1 |
| Ogawa, H | 1 |
| Hiraoka, Y | 1 |
| Kawai, H | 1 |
| Harrison, GS | 1 |
| Green, DF | 1 |
| Newling, DW | 2 |
| Richards, B | 2 |
| Robinson, MR | 2 |
| Smith, PH | 3 |
| Flüchter, SH | 4 |
| Hlobil, H | 1 |
| Harzmann, R | 3 |
| Rothe, KF | 1 |
| Bichler, KH | 4 |
| Hopkins, SC | 1 |
| Buice, RG | 1 |
| Matheny, R | 1 |
| Koontz, WW | 2 |
| Torti, FM | 2 |
| Lum, BL | 1 |
| Otto, U | 1 |
| Droese, M | 1 |
| Klöppel, G | 1 |
| Dhafir, RA | 1 |
| Pfeffer, M | 1 |
| MacDonald, S | 1 |
| Block, A | 1 |
| Dragone, N | 1 |
| Yamanaka, H | 1 |
| Kaburagi, Y | 1 |
| Imai, K | 1 |
| Miki, M | 1 |
| Tiver, KW | 1 |
| Langlands, AO | 1 |
| Carroll, PR | 1 |
| Williams, RD | 1 |
| Kim, MJ | 1 |
| Dombrovskis, S | 1 |
| Cummings, B | 1 |
| Keane, T | 1 |
| Thomas, G | 1 |
| Harwood, A | 1 |
| Rider, W | 1 |
| Prout, GR | 3 |
| Nissenkorn, I | 1 |
| Herrod, H | 1 |
| DeFuria, MD | 2 |
| Crooke, S | 1 |
| Finebaum, P | 1 |
| Wallace, S | 1 |
| Chuang, VP | 1 |
| Samuels, M | 1 |
| Johnson, D | 1 |
| Erdmann, D | 2 |
| Griffin, PP | 1 |
| Nocks, BN | 1 |
| Daly, JJ | 1 |
| Trindade, A | 1 |
| Samuels, ML | 1 |
| Logothetis, CJ | 1 |
| Pavlotsky, A | 2 |
| Eidelman, A | 2 |
| Barak, F | 2 |
| Walach, N | 1 |
| Horn, Y | 2 |
| Manyak, MJ | 1 |
| Maffezzini, M | 1 |
| Simonato, A | 1 |
| Zanon, M | 1 |
| Raber, M | 1 |
| Carmignani, G | 1 |
| Szemes, Z | 1 |
| Kovács, R | 1 |
| Moltó, L | 1 |
| Alvarez-Mon, M | 1 |
| Carballido, J | 1 |
| Olivier, C | 1 |
| Gimeno, F | 1 |
| Manzano, L | 1 |
| Kulaylat, MN | 1 |
| Doerr, R | 1 |
| Butler, B | 1 |
| Satchidanand, SK | 1 |
| Singh, A | 1 |
| Huland, E | 2 |
| Klän, R | 1 |
| Bouffioux, C | 2 |
| Kurth, KH | 3 |
| Bono, A | 1 |
| Kruger, CB | 1 |
| De Pauw, M | 2 |
| Mizutani, Y | 3 |
| Fukumoto, M | 1 |
| Bonavida, B | 2 |
| Yoshida, O | 3 |
| Schmittgen, TD | 2 |
| Weaver, JM | 1 |
| Badalament, RA | 4 |
| Klein, EA | 1 |
| Young, DC | 2 |
| Moyano Calvo, JL | 1 |
| Fernández Arjona, M | 1 |
| Minguez Martínez, R | 1 |
| Rabadan Ruiz, M | 1 |
| Melón Rey, FJ | 1 |
| Herrero Torres, L | 1 |
| Pereira Sanz, I | 1 |
| Minervini, R | 2 |
| Felipetto, R | 2 |
| Viganò, L | 2 |
| Cecchi, M | 1 |
| Fiore, AA | 1 |
| Iorio, B | 1 |
| Vennarecci, G | 1 |
| Venditti, D | 1 |
| Cervelli, V | 1 |
| Giudiceandrea, F | 1 |
| Casciani, CU | 1 |
| Smith, DE | 2 |
| Shah, KH | 1 |
| Rao, AR | 1 |
| Frost, DB | 1 |
| Latino, F | 1 |
| Anderson, PJ | 1 |
| Peddada, AV | 1 |
| Kagan, AR | 1 |
| Llopis, M | 1 |
| Moreno, J | 1 |
| Botella, R | 1 |
| Algado, M | 1 |
| Kapp, KS | 1 |
| Kapp, DS | 1 |
| Stuecklschweiger, G | 1 |
| Berger, A | 1 |
| Geyer, E | 1 |
| Vecchioli Scaldazza, C | 2 |
| Wörle, K | 1 |
| Steinbach, P | 1 |
| Hofstädter, F | 1 |
| Jauhiainen, K | 3 |
| Rintala, E | 3 |
| Eastham, JA | 1 |
| Huffman, JL | 1 |
| Gelabert-Mas, A | 1 |
| Arango Toro, O | 1 |
| Bielsa Gali, O | 1 |
| Lladó Carbonell, C | 1 |
| vd Meijden, AP | 1 |
| Witjes, WP | 3 |
| Doesburg, W | 2 |
| Schaafsma, HE | 1 |
| Debruyne, FM | 6 |
| Borgmann, V | 1 |
| al-Abadi, H | 1 |
| Friedrichs, R | 1 |
| Nagel, R | 1 |
| Hamdy, FC | 1 |
| Hastie, KJ | 1 |
| Kerry, R | 1 |
| Williams, JL | 3 |
| Seaman, EK | 1 |
| Slawin, KM | 1 |
| Weston, PM | 1 |
| Greenland, JE | 1 |
| Naito, S | 2 |
| Hasegawa, S | 1 |
| Yokomizo, A | 1 |
| Koga, H | 1 |
| Kotoh, S | 1 |
| Kuwano, M | 1 |
| Kumazawa, J | 2 |
| Lev, A | 3 |
| Freschi, M | 1 |
| Gallus, G | 1 |
| Parmar, MK | 3 |
| Grigor, KM | 4 |
| Lallemand, G | 1 |
| Benyon, LL | 1 |
| Fellows, J | 1 |
| Freedman, LS | 3 |
| Hall, RR | 3 |
| Hargreave, TB | 4 |
| Munson, K | 1 |
| Rose, MB | 1 |
| Whelan, P | 1 |
| Van der Meijden, AP | 4 |
| Macaluso, MP | 1 |
| Pawinsky, A | 1 |
| Van Glabbeke, M | 1 |
| Vicini, D | 1 |
| Bettaglio, G | 1 |
| Dallera, P | 1 |
| Ruggieri, M | 1 |
| Mirando, P | 1 |
| Franceschetti, GP | 1 |
| Sali, C | 1 |
| Picchio, GL | 1 |
| Dell'Orto, P | 1 |
| D'Addezio, F | 1 |
| Bernardini, P | 1 |
| Mangiarotti, B | 1 |
| Del Nero, A | 1 |
| Pisani, E | 1 |
| Villaronga, A | 1 |
| Bellver, E | 1 |
| Perli, G | 1 |
| Pautaso, O | 1 |
| Bengochea, D | 1 |
| Roldán, RA | 1 |
| Podskubska, O | 1 |
| Belén, R | 1 |
| Delgado, G | 1 |
| Laberti, O | 1 |
| Lando, R | 1 |
| Rey, H | 1 |
| Bengio, R | 1 |
| Minuzzi, L | 1 |
| Goldman, E | 1 |
| Milman, A | 1 |
| Sanguinetti, O | 1 |
| Wernert, O | 1 |
| Pampaloni, S | 1 |
| Fiorentini, L | 1 |
| Bono, AV | 2 |
| Denis, L | 1 |
| Lovisolo, JA | 1 |
| Simak, R | 1 |
| Wiener, H | 2 |
| Foeger, A | 1 |
| Susani, M | 2 |
| Zhang, ZF | 1 |
| Maier, U | 4 |
| Marberger, M | 3 |
| Okamoto, E | 1 |
| Kinne, RK | 1 |
| Sökeland, J | 1 |
| Yen, WC | 2 |
| Schmittgen, T | 1 |
| Klingenberger, HJ | 1 |
| Ulker, V | 1 |
| Apaydin, E | 1 |
| Gürsan, A | 1 |
| Ozyurt, C | 1 |
| Kandiloğlu, G | 1 |
| Paroni, R | 2 |
| Arcelloni, C | 1 |
| De Vecchi, E | 1 |
| Fermo, I | 1 |
| Mauri, D | 1 |
| Fraunholz, IB | 1 |
| Adamietz, IA | 1 |
| Lorenz, M | 1 |
| Staib-Sebler, E | 1 |
| Böttcher, HD | 1 |
| Shimizu, Y | 1 |
| Loh, C | 1 |
| Otto, T | 1 |
| Krege, S | 1 |
| Otto, B | 1 |
| Goepel, M | 1 |
| Rübben, H | 1 |
| Keeley, FX | 1 |
| Bagley, DH | 1 |
| Mian, C | 1 |
| Hofbauer, J | 1 |
| Haitel, A | 1 |
| Brausi, M | 3 |
| Campo, B | 1 |
| Pizzocaro, G | 1 |
| Parma, A | 1 |
| Mazza, G | 1 |
| Vicini, A | 1 |
| Chopin, DK | 1 |
| Solomon, LZ | 1 |
| Jennings, AM | 1 |
| Foley, SJ | 1 |
| Birch, BR | 1 |
| Rohde, D | 1 |
| Raffenberg, G | 1 |
| Kaviani, S | 1 |
| Wolff, J | 1 |
| Jakse, G | 1 |
| Caris, CT | 1 |
| Mungan, NA | 1 |
| Smits, G | 1 |
| Schaafsma, E | 1 |
| Kiemeney, L | 1 |
| Caris, C | 1 |
| Debruyne, F | 1 |
| Doherty, AP | 1 |
| Trendell-Smith, N | 1 |
| Stirling, R | 1 |
| Rogers, H | 1 |
| Bellringer, J | 1 |
| Mauroy, B | 1 |
| Bonnal, JL | 1 |
| Prevost, B | 1 |
| Chive, M | 1 |
| Lhotellier, V | 1 |
| Sozanski, JP | 1 |
| Vanseymortier, L | 1 |
| Stefaniak, X | 1 |
| Ferraris, V | 1 |
| Serao, A | 1 |
| Buffa, G | 1 |
| Weaver, JR | 1 |
| Kondás, J | 1 |
| Kiss, L | 1 |
| Határ, A | 1 |
| Kiss, A | 1 |
| Lukács, T | 1 |
| Szeldeli, P | 1 |
| Törzsök, F | 1 |
| Bodrogi, I | 1 |
| Williamson, KE | 2 |
| Weir, HP | 1 |
| McManus, DT | 1 |
| Hamilton, PW | 1 |
| Keane, PF | 2 |
| Johnston, SR | 2 |
| Baselli, EC | 2 |
| Greenberg, RE | 2 |
| Chen, S | 1 |
| Lin, Z | 1 |
| Xu, E | 1 |
| Li, Q | 1 |
| Xu, X | 1 |
| Neulander, EZ | 1 |
| Lismer, L | 1 |
| Kaneti, J | 1 |
| Cliff, AM | 1 |
| Heatherwick, B | 1 |
| Scoble, J | 1 |
| Parr, NJ | 1 |
| Warner, JA | 1 |
| Venema, PL | 1 |
| Pollifrone, DL | 1 |
| Harbrecht, JD | 1 |
| Chin, JL | 1 |
| Miles, BJ | 1 |
| Sakamoto, N | 1 |
| Ariyoshi, A | 1 |
| Osada, Y | 1 |
| Omoto, T | 1 |
| Fujisawa, Y | 1 |
| Morita, I | 1 |
| Yamashita, H | 1 |
| Sun, HZ | 1 |
| Wu, SF | 1 |
| Tu, ZH | 1 |
| Duggan, BJ | 1 |
| Anderson, NH | 1 |
| Moffitt, DD | 1 |
| Peake, D | 1 |
| Cighetti, G | 1 |
| Montorsi, F | 1 |
| Masters, JR | 3 |
| Sekine, H | 1 |
| Ohya, K | 1 |
| Kojima, SI | 1 |
| Igarashi, K | 1 |
| Fukui, I | 1 |
| Raitanen, MP | 1 |
| Hellström, P | 1 |
| Marttila, T | 1 |
| Korhonen, H | 2 |
| Talja, M | 1 |
| Ervasti, J | 1 |
| Tammela, TL | 1 |
| Mack, D | 1 |
| Hall, R | 1 |
| de Balincourt, C | 1 |
| Zang, Z | 1 |
| Xu, H | 1 |
| Yu, L | 1 |
| Yang, D | 1 |
| Xie, S | 1 |
| Shi, Y | 1 |
| Li, Z | 1 |
| Li, J | 1 |
| Wang, J | 1 |
| Li, M | 1 |
| Guo, Y | 1 |
| Gu, F | 1 |
| Dunst, J | 2 |
| Diestelhorst, A | 1 |
| Heynemann, H | 1 |
| Schrott, KM | 1 |
| Sauer, R | 2 |
| Malmström, PU | 1 |
| Fuse, H | 1 |
| Sakai, T | 1 |
| Kimura, H | 1 |
| Katayama, T | 1 |
| Wang, SH | 1 |
| van der Meijden, PM | 1 |
| Roos, EP | 1 |
| Steerenberg, PA | 2 |
| Sahashi, M | 2 |
| Ono, Y | 2 |
| Matsuura, O | 1 |
| Ohshima, S | 2 |
| Fukushima, M | 1 |
| Pagano, F | 2 |
| Bassi, P | 2 |
| Milani, C | 2 |
| Piazza, N | 2 |
| Meneghini, A | 2 |
| Garbeglio, A | 2 |
| Tsushima, T | 1 |
| Nasu, Y | 1 |
| Abeki, N | 1 |
| Noda, M | 1 |
| Saika, T | 1 |
| Ohmori, H | 1 |
| Kobashi, K | 1 |
| Ozaki, Y | 1 |
| Matsumura, Y | 1 |
| Tanahashi, T | 1 |
| Busemann, E | 1 |
| Gerdes, J | 1 |
| Ulmer, AJ | 1 |
| Flad, HD | 1 |
| Jocham, D | 1 |
| Uemura, M | 1 |
| Kasamatsu, Y | 1 |
| Sawada, M | 1 |
| Takemura, S | 1 |
| Sugino, S | 1 |
| Kondou, M | 1 |
| Droller, MJ | 3 |
| Flanigan, RC | 2 |
| Nseyo, UO | 1 |
| Höbarth, K | 1 |
| Alfthan, O | 3 |
| Wu, JJ | 1 |
| Yin, ZL | 1 |
| Zhu, JN | 1 |
| Cho, YH | 1 |
| Straight, RC | 1 |
| Smith, JA | 1 |
| Doci, R | 1 |
| Zucali, R | 1 |
| Bombelli, L | 1 |
| Montalto, F | 1 |
| Lamonica, G | 1 |
| Zattoni, F | 1 |
| Maruzzi, D | 1 |
| Drago-Ferrante, GL | 1 |
| da Silva, FC | 1 |
| Ferrito, F | 1 |
| Brandão, T | 1 |
| Santos, A | 1 |
| Rajala, P | 1 |
| Nurmi, M | 1 |
| Lähde, M | 1 |
| Richie, JP | 1 |
| Thrasher, JB | 1 |
| Brosman, SA | 1 |
| Oliver, RT | 1 |
| Nio, Y | 1 |
| Tarkington, M | 1 |
| Sommers, CL | 1 |
| Gelmann, EP | 1 |
| Tefft, MC | 1 |
| Lynch, JH | 1 |
| Hansson, E | 1 |
| Juusela, H | 1 |
| Kanerva, K | 1 |
| Permi, J | 1 |
| Sotarauta, M | 1 |
| Vaalasti, T | 1 |
| Hörbarth, K | 1 |
| Jauhiainen, KE | 1 |
| Alfthan, OS | 1 |
| Foo, KT | 1 |
| Tan, EC | 1 |
| Tung, KH | 1 |
| Tock, EP | 1 |
| Megias Garrigós, J | 1 |
| Pelluch Auladell, A | 1 |
| Romero Pérez, P | 1 |
| Fernandez García, J | 1 |
| Gassó Matoses, M | 1 |
| Sánchez Marcos, M | 1 |
| Mira Llinarés, A | 1 |
| Arregui, MA | 1 |
| Aguirre, A | 1 |
| Gil, N | 1 |
| Goday, J | 1 |
| Ratón, JA | 1 |
| Drago, JR | 2 |
| Seraphim, LA | 1 |
| Perrapato, SD | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Koseki, K | 1 |
| Irisawa, C | 1 |
| Shiraiwa, Y | 1 |
| Yabusaki, N | 1 |
| Komatsu, H | 1 |
| Tago, K | 1 |
| Yamada, Y | 1 |
| Ueno, A | 1 |
| Pisters, LL | 1 |
| Tykochinsky, G | 1 |
| Miura, K | 1 |
| Yuri, Y | 1 |
| Tsukada, T | 1 |
| Schneider, A | 1 |
| Arndt, R | 1 |
| Mitsuzane, K | 1 |
| Kawabata, M | 1 |
| Terada, M | 1 |
| Nomura, S | 1 |
| Sato, M | 1 |
| Yamada, R | 1 |
| Gelabert Mas, A | 1 |
| Arango, O | 1 |
| Rosales, A | 1 |
| Coronado, J | 1 |
| Moreno, A | 1 |
| Uchida, T | 1 |
| Kobayashi, K | 1 |
| Honda, N | 1 |
| Arakawa, T | 1 |
| Omata, T | 1 |
| Endo, T | 1 |
| Ishibashi, A | 1 |
| Koshiba, K | 1 |
| Fujita, T | 1 |
| Aso, Y | 1 |
| Aota, Y | 1 |
| Murase, T | 1 |
| Takashi, M | 1 |
| Ito, H | 2 |
| Shimoji, T | 1 |
| Miyake, K | 1 |
| Mitsuya, H | 1 |
| Russell, KJ | 1 |
| Koh, WJ | 1 |
| Russell, AH | 1 |
| Griffin, BR | 1 |
| Markette, KL | 1 |
| Tong, DY | 1 |
| Griffin, TW | 1 |
| Baumgartner, G | 1 |
| Giesbers, AA | 1 |
| Van Helsdingen, PJ | 3 |
| Kramer, AE | 1 |
| Alon, H | 1 |
| Irwin, R | 1 |
| Zincke, H | 2 |
| Kubota, Y | 1 |
| Kakizaki, H | 1 |
| Numasawa, K | 1 |
| Suzuki, K | 1 |
| Kato, H | 1 |
| Steimann, J | 1 |
| Strohmaier, WL | 1 |
| Ikubo, A | 1 |
| Miyazaki, K | 1 |
| Jordan, AM | 1 |
| Franssen, MP | 2 |
| Drago, PC | 1 |
| Lucas, J | 1 |
| Farha, AJ | 1 |
| Krauss, DJ | 1 |
| Zhou, CL | 1 |
| Weaver, DJ | 2 |
| Barrett, BA | 2 |
| Ross, G | 2 |
| Adelstein, EH | 2 |
| Harima, Y | 1 |
| Nakagawa, S | 1 |
| Shiraishi, T | 1 |
| Murata, T | 1 |
| Harima, K | 1 |
| Sawada, S | 1 |
| Tanaka, T | 1 |
| Kobayashi, S | 1 |
| Streem, SB | 1 |
| Pontes, EJ | 1 |
| Blatnik, AF | 2 |
| Shelton, TB | 1 |
| Mobley, WC | 1 |
| Loening, SA | 1 |
| Narayana, AS | 1 |
| Culp, DA | 1 |
| Cant, JD | 1 |
| Muff, NS | 1 |
| Shetabi, H | 1 |
| Ellison, MF | 1 |
| Butler, KM | 1 |
| Gomella, LG | 1 |
| McRoberts, JW | 1 |
| Groos, E | 2 |
| Rikken, CH | 2 |
| Walker, L | 1 |
| Wilhelms, E | 2 |
| Criée, CP | 2 |
| Neubauer, H | 2 |
| Neuhaus, KL | 2 |
| Smith, G | 1 |
| Elton, RA | 1 |
| Chisholm, GD | 1 |
| Newsam, JE | 1 |
| Levin, DR | 1 |
| Araki, S | 1 |
| Numa, H | 1 |
| Okada, K | 1 |
| John, MJ | 1 |
| Flam, M | 1 |
| Lovalvo, L | 1 |
| Mowry, PA | 1 |
| Orihuela, E | 1 |
| Crowley, AR | 1 |
| Perry, A | 2 |
| Blech, M | 1 |
| Truss, F | 1 |
| Konowalchuk, TW | 1 |
| Elhilali, M | 1 |
| Mackillop, WJ | 1 |
| Reichard, U | 1 |
| Wolf, N | 1 |
| Baker, WC | 1 |
| Russo, MA | 1 |
| deVere White, RW | 1 |
| Uekado, Y | 1 |
| Shinka, T | 1 |
| Hirano, A | 1 |
| Ohkawa, T | 1 |
| Isaka, S | 1 |
| Okano, T | 1 |
| Shimazaki, J | 1 |
| Igarashi, T | 1 |
| Murakami, S | 1 |
| Higa, T | 1 |
| Ishikawa, T | 1 |
| Zama, S | 1 |
| Kataumi, S | 1 |
| Kataumi, Z | 1 |
| Hirao, Y | 1 |
| Okajima, E | 1 |
| Ohara, S | 1 |
| Ozono, S | 1 |
| Hiramatsu, T | 1 |
| Yoshida, K | 2 |
| Yamada, K | 1 |
| Aoyama, H | 1 |
| Hashimoto, M | 1 |
| Watanabe, S | 1 |
| Smith, AY | 1 |
| Vitale, PJ | 1 |
| Lowe, BA | 1 |
| Woodside, JR | 1 |
| Alter, AJ | 1 |
| Malek, GH | 1 |
| Hickey, DP | 1 |
| Tari, K | 1 |
| Satake, I | 1 |
| Kojima, S | 1 |
| Negishi, T | 1 |
| Nakame, Y | 1 |
| Kanaoya, F | 1 |
| Horiuchi, S | 1 |
| Saito, T | 1 |
| Owada, F | 1 |
| Inglis, JA | 1 |
| Heney, NM | 2 |
| Kawano, S | 1 |
| Yano, S | 1 |
| Sakamoto, S | 1 |
| Ogata, J | 1 |
| Sleeboom, HP | 1 |
| de Bruyn, EA | 1 |
| Tjaden, UR | 2 |
| Schreinemachers, LM | 1 |
| Geboers, AD | 1 |
| van Leeuwen, MJ | 1 |
| de Jong, WH | 1 |
| Ruitenberg, EJ | 1 |
| Hardeman, SW | 1 |
| Uscinska, BM | 1 |
| Barton, B | 1 |
| Soloway, M | 1 |
| Trump, DL | 1 |
| Hazra, T | 1 |
| Weinstein, RS | 1 |
| Sato, K | 1 |
| Hatano, T | 1 |
| Miyazato, T | 1 |
| Saito, S | 1 |
| Kashiwabara, N | 1 |
| Igarashi, M | 1 |
| Koyama, Y | 1 |
| Hayakawa, M | 1 |
| Osawa, A | 1 |
| Hu, KN | 1 |
| Kim, A | 1 |
| Khan, AS | 1 |
| Soroff, H | 1 |
| Gonder, M | 1 |
| Leichman, L | 1 |
| Nigro, N | 1 |
| Vaitkevicius, VK | 1 |
| Considine, B | 1 |
| Buroker, T | 1 |
| Bradley, G | 1 |
| Seydel, HG | 1 |
| Olchowski, S | 1 |
| Cummings, G | 1 |
| Leichman, C | 1 |
| MacFarlane, JR | 1 |
| Strobel, SL | 1 |
| Tuttle, SE | 1 |
| Wise, HA | 1 |
| Sharma, HM | 1 |
| de Wall, JG | 1 |
| van Oosterom, AT | 1 |
| de Jong, EA | 1 |
| Benson, RC | 1 |
| Hilton, JF | 1 |
| Taylor, WF | 1 |
| Walsh, PC | 1 |
| Whitmore, WF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252] | Phase 3 | 102 participants (Anticipated) | Interventional | 2022-05-07 | Recruiting | ||
| Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer[NCT02716961] | 208 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)[NCT02695771] | Phase 3 | 101 participants (Actual) | Interventional | 2016-04-19 | Completed | ||
| Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869] | Phase 3 | 300 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| Intravesical Electromotive Mitomycin for High Risk Urothelial Non-muscle Invasive Bladder Cancer After Intravesical Bacillus Calmette-Guérin Failure[NCT04311580] | Phase 2 | 52 participants (Actual) | Interventional | 2000-01-01 | Completed | ||
| Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume in Patients With Non-muscle Invasive Bladder Cancer Patients[NCT05701332] | Phase 4 | 25 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study[NCT01442519] | Phase 3 | 212 participants (Actual) | Interventional | 1994-01-31 | Completed | ||
| Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC[NCT03348969] | Phase 4 | 120 participants (Actual) | Interventional | 2017-11-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03 (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 24 |
| Gemcitabine | 23 |
| No Intervention | 25 |
The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death. (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 15 |
| Gemcitabine | 14 |
| No Intervention | 20 |
52 reviews available for mitomycin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Drug instillation in the management of urinary tract urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Instillation, Drug; Kidney; Mitomycin; Neoplasm Recurrence, Lo | 2022 |
Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Mitomy | 2022 |
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Topics: Carcinoma, Transitional Cell; Humans; Kidney; Kidney Neoplasms; Mitomycin; Multicenter Studies as To | 2023 |
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell | 2020 |
Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
Topics: Administration, Intravesical; Antineoplastic Agents; Aziridines; BCG Vaccine; Carcinoma, Transitiona | 2020 |
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Delayed-Action | 2020 |
Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Fever; Humans; Incidence; Kidney | 2021 |
Nephron-sparing management of upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 2021 |
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2017 |
[Radiochemotherapy for invasive bladder cancer : An update].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Chemoradio | 2018 |
[Immediate post TURBT MMC instillation.]
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2018 |
Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibodies, Monoclonal; Antibodies, Monoclonal | 2018 |
Urothelial carcinoma in children, case report with review of literature.
Topics: Administration, Intravesical; Adolescent; Age of Onset; Antibiotics, Antineoplastic; Carcinoma, Tran | 2019 |
Risk-adapted strategy for the kidney-sparing management of upper tract tumours.
Topics: Administration, Intravesical; Algorithms; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; | 2015 |
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2016 |
WITHDRAWN: Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T I bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2015 |
Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Chemotherapy, Adjuva | 2012 |
Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2013 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deox | 2013 |
Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2003 |
[Cyclophosphamide-induced bladder cancer: three case reports].
Topics: Administration, Intravesical; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; | 2003 |
Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carc | 2004 |
Intravesical mitomycin C for superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Tr | 2006 |
Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Male; Mitomycin; Neoplasm Recurr | 2006 |
Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Hu | 2008 |
Treatment of superficial carcinoma of the bladder.
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Carcinoma in Situ; Carcinoma, Transitional Cell; Comb | 1984 |
Systemic therapy of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transit | 1984 |
Current topics in the pathology of bladder cancer.
Topics: Carcinoma in Situ; Carcinoma, Transitional Cell; Chromosome Aberrations; Chromosomes, Human, 1-3; Cy | 1983 |
The biology and treatment of superficial bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Squamous Cell; Carcinoma, Trans | 1984 |
Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous C | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Cisplati | 1984 |
Squamous cell carcinoma complicating idiopathic inflammatory bowel disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transiti | 1995 |
Papillary-like bladder calcifications following intravescical mitomycin C. A case report.
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Therapy; H | 1993 |
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; | 1994 |
Treatment options for upper tract transitional-cell carcinoma.
Topics: Administration, Topical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Human | 1993 |
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; C | 1997 |
[Intravesical instillation in the treatment of superficial tumors of the bladder].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma; Carcinoma, Transi | 1998 |
Intravesical therapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic | 2000 |
Maintenance therapy for superficial bladder cancer.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; H | 2001 |
Radiochemotherapy for T1G3 bladder cancer.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined | 2002 |
BCG in superficial bladder cancer: a review of phase III European trials.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
[A case of secondary myelodysplastic syndrome following chemotherapy for lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio | 1992 |
Managing superficial bladder cancer: an overview.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Comb | 1992 |
Intravesical chemotherapy. Treatment selection, techniques, and results.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell | 1992 |
Complications of intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epir | 1992 |
Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
[Calcified bladder lesions secondary to the instillation of mitomycin C].
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Comb | 1991 |
Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1989 |
Intravesical chemotherapy: how effective is it?
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Doxorubicin; Humans; Mitomy | 1988 |
Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Drug Administr | 1988 |
Introduction and overview of intravesical therapy for superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubi | 1988 |
84 trials available for mitomycin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Topics: Aged; Brachytherapy; Carcinoma, Transitional Cell; Gemcitabine; Humans; Mitomycin; Radiation Oncolog | 2023 |
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 2013 |
Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combi | 2014 |
Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.
Topics: Administration, Intravesical; Aged; Animals; Carcinoma, Transitional Cell; Combined Modality Therapy | 2015 |
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Carcinoma, Tran | 2007 |
[Therapeutic effect of mitomycin C in the immediate postoperative period in patients with intermediate-risk non-muscle-invasive bladder tumors].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Humans; | 2008 |
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; De | 2010 |
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional | 2013 |
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Analysis of Variance; Antineoplastic Combined Chemothera | 2013 |
[Prevention of postoperative recurrence of human bladder carcinoma by intravesical instillation of immunotoxin, a clinical study].
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Immun | 2003 |
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
[Oral tegafur plus mitomycin versus intravesical mitomycin alone in the prevention of recurrence in stage Ta bladder tumors].
Topics: Administration, Intravesical; Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agen | 2003 |
Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Aged; Antibiotic Prophylaxis; Antibiotics, Antineoplastic; Carcinoma, | 2003 |
Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma | 2004 |
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit | 2004 |
A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional C | 2005 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Intravesical adjuvant therapy using mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell | 2006 |
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2006 |
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Ca | 2007 |
The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell | 2007 |
[Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2008 |
Intravesical chemotherapy for superficial bladder cancer.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Ethoglucid; Follow | 1984 |
Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
[Clinical trials with localized mitomycin instillation therapy for superficial urothelial bladder carcinoma].
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials as Topic; Follow-Up St | 1982 |
Local mitomycin-C therapy in relapse-prevention of superficial bladder neoplasms treated by means of laser.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Humans; Injections, Intra | 1994 |
Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carci | 1995 |
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Chemotherapy, A | 1995 |
[Prospective and randomized study comparing mitomycin C and interferon alpha 2b in the prevention of superficial tumors of the bladder].
Topics: Adolescent; Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Interferon alpha-2; Interfero | 1994 |
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; | 1994 |
[Prophylaxis of transitional cell carcinoma of the bladder G1-G2; pTa-pT1 with mitomycin C or interferon alpha-2a. Preliminary data].
Topics: Carcinoma, Transitional Cell; Combined Modality Therapy; Follow-Up Studies; Humans; Interferon alpha | 1993 |
Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1993 |
[A prospective and randomized study of the complete response, index of recurrences and progression in superficial bladder carcinoma treated with mitomycin C alone versus mitomycin C and BCG alternatively].
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Chi-Square Distribution; Drug Therapy, Combination; Femal | 1993 |
A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Cy | 1993 |
Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined | 1996 |
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 1996 |
Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 3089
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 1996 |
[Mitomycin C for the treatment of superficial tumors of the bladder (Tis-Ta-T1) with one or more risk factors. Argentinian Cooperative Group of Oncourology (GCAO)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Follow-Up Studies; H | 1996 |
Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.
Topics: Administration, Intravesical; Analysis of Variance; Antibiotic Prophylaxis; Antibiotics, Antineoplas | 1996 |
Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug | 1996 |
[Mitomycin-C 30 mg for 12 months versus Mitomycin-C 40 mg for 6 months in the prevention of superficial bladder carcinoma G1-G2].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell | 1996 |
Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 1997 |
[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Resistance, | 1997 |
Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Elect | 1998 |
Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carc | 1998 |
Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Dise | 1998 |
The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Hun | 1999 |
[Long-term results of intravesical N-CWS instillation to prevent recurrence after surgery for bladder cancer].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carc | 1997 |
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2001 |
Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, | 2001 |
A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2001 |
Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2001 |
Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma | 2001 |
A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; | 2002 |
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; | 1992 |
Combination chemotherapy for advanced urothelial-tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1992 |
BCG in superficial bladder cancer: a review of phase III European trials.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
[Prophylactic intravesical instillation therapy in patients with superficial bladder cancer--results of a randomized prospective study].
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Doxorubicin; Drug Administration Schedul | 1992 |
4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Epirubicin | 1992 |
Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Immun | 1991 |
Instillation therapy in superficial urinary bladder cancer. Finnbladder Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Combined | 1991 |
[Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Topics: Administration, Intravesical; Adult; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Drug Administr | 1991 |
Immunocytology as a possible marker to identify patients who require prophylaxis.
Topics: Administration, Intravesical; Aged; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; C | 1990 |
Approaches to the treatment of bladder cancer at Stanford.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Carcin | 1987 |
Three-drug combination chemotherapy for advanced urothelial tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell | 1987 |
Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined Modality Therapy; Doub | 1989 |
Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Transiti | 1989 |
Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical | 1989 |
Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cystoscopy; Follow-Up Studies; Humans; M | 1989 |
BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Papillary; Carcinoma, Transitional Cell; Clini | 1989 |
A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; Mitomycin; Mitomycins; Neoplasm Recu | 1986 |
Prophylaxis of superficial bladder cancer with instillation of adriamycin or mitomycin C.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1987 |
Prophylactic treatment for superficial bladder cancer following transurethral resection.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Mo | 1987 |
Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Drug Administr | 1988 |
Mitomycin C resorption following repeated intravesical instillations using different instillation times.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials | 1988 |
BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Topics: Administration, Intravesical; Animals; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; | 1988 |
Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transi
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined Modal | 1988 |
Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical | 1988 |
Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; Mitomy | 1988 |
Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1985 |
249 other studies available for mitomycin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Topics: Carcinoma, Transitional Cell; Female; Humans; Hydrogels; Kidney Neoplasms; Male; Mitomycin; Ureteral | 2022 |
Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".
Topics: Carcinoma, Transitional Cell; Female; Humans; Male; Mitomycin; Urinary Bladder Neoplasms; Urothelium | 2022 |
Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm).
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Mitomycin; Reactive Oxygen Specie | 2022 |
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
Topics: Carcinoma, Transitional Cell; Constriction, Pathologic; Humans; Mitomycin; Nephrostomy, Percutaneous | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Topics: Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Constriction, Pathologic; Humans; Kidney Neopl | 2023 |
A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurrence, Local; Nephroureterectomy; Ret | 2023 |
Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma.
Topics: Animals; Carcinoma, Transitional Cell; Drug-Eluting Stents; Female; Fibroins; Mitomycin; Models, Ani | 2023 |
Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Hum | 2023 |
The patient experience with localized upper tract urothelial cancer.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Patient Outco | 2023 |
Comment on: "Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma".
Topics: Animals; Carcinoma, Transitional Cell; Combined Modality Therapy; Mitomycin; Urinary Bladder Neoplas | 2023 |
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Nephrons; Retrospective Studies; | 2023 |
The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Hum | 2023 |
Demographics, pathological characteristics and survival in urothelial bladder cancer in a cohort of Sri Lankan patients.
Topics: Aged; Carcinoma, Transitional Cell; Demography; Female; Humans; Male; Mitomycin; Neoplasm Recurrence | 2022 |
Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A | 2019 |
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Prospective Studies; Ureteral Neoplasms; Ureterosco | 2020 |
New mitomycin formulation for low-grade upper tract urothelial cancer.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Urologic Neoplasms; Urothelium | 2020 |
Response to Okeke and Rai:"Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Center Prospective Nonrandomized Trial" by Gallioli et al.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Prospective Studies; Ureteral Neoplasms; Ureterosco | 2020 |
Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Femal | 2020 |
The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 2021 |
Re: Primary Chemoablation of Low-grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-containing Reverse Thermal Gel (OLYMPUS): An Open-label, Single-arm, Phase 3 Trial.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin | 2021 |
Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemothera | 2017 |
Editorial Comment on: Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes by Metcalfe et al.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplas | 2017 |
American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA).
Topics: Acetanilides; Administration, Intranasal; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carc | 2017 |
Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 2017 |
Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell | 2018 |
Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2018 |
Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
Topics: Administration, Intravesical; Age Factors; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitiona | 2018 |
Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2018 |
Salvage topical therapy for upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG | 2018 |
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Kidney Function Tests; Kidney Ne | 2018 |
Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; | 2019 |
Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2013 |
Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)--avoidance, recognition, management and consent.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Informed Consent; Male; Middle Aged; Mito | 2014 |
The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: an in vitro study.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Transitional Cell; Cell Line, Tumor; Cel | 2014 |
Predicting factors for recurrence in low-grade Ta primary bladder tumours.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Ce | 2014 |
Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biomarkers, Tumo | 2015 |
Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Heterografts; Humans; In | 2015 |
Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer.
Topics: ABO Blood-Group System; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherap | 2015 |
Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
Re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
Topics: Adjuvants, Immunologic; Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BC | 2016 |
Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Blotting, Western; Carci | 2016 |
Re: Sequential Intravesical Mitomycin plus Bacillus Calmette-Guérin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma, Transitional | 2016 |
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; BCG Vaccine; Biomarkers; C-Reactive Protein; Ca | 2016 |
Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.
Topics: Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Cross-Linking Reagents; Delayed | 2017 |
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2017 |
Vesicoenteric, vesicovaginal, vesicocutaneous fistula -an unusual complication with intravesical mitomycin.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell | 2008 |
Prevention and treatment of transitional cell carcinomatosis with intraperitoneal chemotherapy in a rat model.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Disease Models, Animal; Mitomyci | 2009 |
[Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2009 |
[Urinary tuberculosis caused by Mycobacterium bovis BCG variety, following intravesical instillation].
Topics: Administration, Intravesical; Aged; Antitubercular Agents; BCG Vaccine; Carcinoma, Transitional Cell | 2010 |
Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Resistance, Neopla | 2009 |
Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy.
Topics: Administration, Intravesical; Aminolevulinic Acid; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; | 2010 |
Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2010 |
Editorial comment.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2010 |
[Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transit | 2010 |
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Tr | 2011 |
Superficial bladder tumours: recurrence and progression.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; Carcinoma, Transitional Cell; C | 2011 |
Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Femal | 2011 |
Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Electrochem | 2011 |
Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Car | 2011 |
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Synergism; Drug Therapy, Combination | 2011 |
[European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract].
Topics: BCG Vaccine; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Diagnostic Ima | 2012 |
Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer.
Topics: Aged; Apoptosis; Caco-2 Cells; Carcinoma, Transitional Cell; Cell Line, Tumor; CpG Islands; DNA Meth | 2012 |
Engagement of integrinβ1 induces resistance of bladder cancer cells to mitomycin-C.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Caspase 10; | 2012 |
Role of positron emission tomography-computed tomography in the management of anal cancer.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2012 |
Histological changes due to intravesical instillation of mitomycin C.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherap | 2012 |
Chemotherapy sorting can be used to identify cancer stem cell populations.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Cycle; Cell Line, Tumor; Drug Therapy; Gen | 2012 |
Conservative nephron-sparing treatment of upper-tract tumors.
Topics: Administration, Topical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chemother | 2013 |
Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2003 |
Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2003 |
Apoptosis of bladder cancer cells induced by short-term and low-dose Mitomycin-C: potential molecular mechanism and clinical implication.
Topics: Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Transitional Cell; Caspase 3; Caspases; Cell Line | 2003 |
Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 2003 |
Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma.
Topics: Adenocarcinoma; Administration, Intravesical; Aged; Antineoplastic Agents, Alkylating; BCG Vaccine; | 2003 |
Combined intravesical hyperthermia and mitomycin chemotherapy: a preliminary in vivo study.
Topics: Adipose Tissue; Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Biopsy; Carcinom | 2003 |
Intravesical therapy for superficial bladder cancer: slow but steady progress.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2003 |
T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic | 2004 |
Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Endo | 2004 |
Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
Topics: Aged; Alternative Splicing; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma in Situ; Carci | 2004 |
Adjuvant topical treatment of upper urinary tract urothelial tumours.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2004 |
NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.
Topics: Carcinoma, Transitional Cell; Genotype; Humans; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Neoplasm | 2004 |
Allergic contact sensitization from intravesical mitomycin C, without dermatitis.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug | 2004 |
Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Effects of intravesical chemotherapy and immunotherapy on semen analysis.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Antibiotics, Antineoplastic; BCG Vaccin | 2005 |
[Toxicity attenuation and efficacy potentiation effects of sijunzi decoction on bladder carcinoma treated by chemotherapy in mice].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cel | 2005 |
Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Line, | 2005 |
Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Dose-Res | 2005 |
Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cystectomy; | 2005 |
Conservative treatment of high grade superficial bladder tumours.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplas | 2005 |
Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Proliferation; Cell Survival; Cost S | 2006 |
Intraperitoneal chemotherapy for the prevention of transitional cell carcinoma implantation.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Injections, Intraperitoneal; Mit | 2006 |
Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitiona | 2006 |
Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Clin | 2006 |
Smac/DIABLO promotes mitomycin C-induced apoptosis of bladder cancer T24 cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proli | 2006 |
[Bladder cancer with skin metastasis: a case report].
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 2006 |
Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurr | 2007 |
Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder c
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Huma | 2007 |
[Overexpression of PTEN gene inhibits proliferation of bladder transitional carcinoma cell line EJ].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Transit | 2007 |
Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Dose-Response Relations | 2007 |
Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; B | 2007 |
Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma, Transitio | 2007 |
Holmium laser treatment for low grade, low stage, noninvasive bladder cancer with local anesthesia and early instillation of mitomycin C.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Anesthesia, Local; Carcinoma, Transitional Ce | 2007 |
Pneumoperitoneum with carbon dioxide inhibits macrophage tumor necrosis factor-alpha secretion: source of transitional-cell carcinoma port-site metastasis, with prophylactic irrigation strategies to decrease laparoscopic oncologic risks.
Topics: Animals; Anti-Infective Agents, Local; Antibiotics, Antineoplastic; Carbon Dioxide; Carcinoma, Trans | 2008 |
In vitro chemosensitivity of human bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Survival; Cel | 1983 |
[Chemosensitivity in established human bladder carcinoma and HELA cell lines in vitro].
Topics: Antineoplastic Agents; Bleomycin; Carbazilquinone; Carcinoma, Transitional Cell; Cell Division; Cell | 1983 |
Microcapsule chemoembolization therapy: a new approach to bladder cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1984 |
Dermatitis due to mitomycin bladder instillations.
Topics: Aged; Carcinoma, Transitional Cell; Drug Eruptions; Humans; Male; Mitomycin; Mitomycins; Urinary Bla | 1984 |
Chemoimmunotherapy of implanted murine bladder cancer.
Topics: Animals; Carcinoma, Transitional Cell; Drug Therapy, Combination; Female; Levamisole; Mice; Mice, In | 1983 |
Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Evaluation; Drug Therapy, Combination; Hum | 1983 |
Prostatic recurrences in the management of superficial bladder tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; M | 1983 |
Severely contracted bladder following intravesical mitomycin C therapy.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Contracture; Humans; Male; Mitomyci | 1983 |
Intravesical instillation of mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Neopla | 1983 |
Mixed adenocarcinoma and anaplastic transitional cell carcinoma of the urinary bladder.
Topics: Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Humans; Male; Mitomycin; Mitomycins; Urinary Bla | 1983 |
[Intracavitary instillation for bladder tumor with antitumor agent. 5th Report: Difference of the action of mitomycin C on normal bladder and tumor of the bladder (experimental and clinical study)].
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Humans | 1983 |
A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
Topics: Carcinoma in Situ; Carcinoma, Transitional Cell; Cystitis; Drug Evaluation; Drug Implants; Erythema; | 1983 |
[Blood and tissue levels of mitomycin C after intravesical instillation].
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomycins; Urinary Bl | 1983 |
The stability and antitumor activity of recycled (intravesical) mitomycin C.
Topics: Animals; Carcinoma, Transitional Cell; Chromatography, High Pressure Liquid; Drug Stability; FANFT; | 1984 |
Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors.
Topics: Antibiotics, Antineoplastic; Bone Marrow; Carcinoma, Transitional Cell; Combined Modality Therapy; D | 1984 |
Superficial bladder cancer: comments on evaluation and management.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Mitomy | 1984 |
[Experimental and clinical studies on intravesical instillation therapy for bladder cancer].
Topics: Adolescent; Adult; Aged; Carbazilquinone; Carcinoma, Transitional Cell; Cytodiagnosis; Doxorubicin; | 1983 |
Mitomycin C reused: an in vitro cost-effectiveness study.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Survival; Costs and Cost Analysis; D | 1984 |
Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Car | 1984 |
Side effects associated with intravesical mitomycin.
Topics: Aged; Carcinoma, Transitional Cell; Drug Eruptions; Female; Humans; Male; Middle Aged; Mitomycin; Mi | 1981 |
The effect of mitomycin C on superficial bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Humans; | 1981 |
Transcatheter intraarterial infusion of chemotherapy in advanced bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Thera | 1982 |
Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Resistance; Female; Humans; Male; | 1982 |
[Recurrence rate in adjuvant local chemotherapy of bladder cancer with mitomycin C].
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomyc | 1982 |
Chemotherapy of carcinoma of renal pelvis: preliminary report.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1981 |
Long-term follow-up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cystosco | 1995 |
Bladder carcinoma--the good, the bad and the ugly.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1996 |
Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 1996 |
Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Female; Humans; Immunotherapy; Int | 1995 |
Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Northern; Carcinoma, Transitional Cell; Cisplatin; D | 1994 |
Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology.
Topics: Autoradiography; Carcinoma, Transitional Cell; Culture Techniques; Drug Resistance; Humans; Immunohi | 1994 |
Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Follow-Up Stu | 1994 |
Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1994 |
Incrusted cystitis after intravesical mitomycin C treatment.
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Therapy; C | 1993 |
The combined effects of high-energy shock waves and cytostatic drugs or cytokines on human bladder cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cytokines | 1994 |
Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Instillati | 1993 |
Effect of different local and systemic therapy upon urinary bladder cytology.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; DNA, Ne | 1993 |
Mitomycin-C in superficial bladder cancer. Is long-term maintenance therapy worthwhile after initial treatment?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; | 1993 |
Role of topical mitomycin C in upper urinary tract transitional cell carcinoma.
Topics: Administration, Topical; Aged; Carcinoma, Transitional Cell; Female; Humans; Kidney Neoplasms; Mitom | 1993 |
Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette | 1995 |
[pT1G3 tumor of the bladder].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitio | 1996 |
[pT1G3 bladder carcinoma: our experience].
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; C | 1996 |
Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy.
Topics: Administration, Intravesical; Aged; Aneuploidy; Antibiotics, Antineoplastic; Carcinoma, Transitional | 1996 |
Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Division; Doxorubicin; Humans; Interferon- | 1996 |
Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Division; Humans; Hydrogen-Ion Conce | 1996 |
Eosinophilic cystitis induced by mitomycin-C.
Topics: Administration, Intravesical; Biopsy; Carcinoma, Transitional Cell; Cystitis; Eosinophilia; Female; | 1996 |
Pharmacodynamic evaluation of mitomycin C analog BMS-181174 for potential use in intravesical bladder cancer therapy.
Topics: Administration, Intravesical; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Carcinoma | 1997 |
Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chromatography, High Pressure Liquid; Hum | 1997 |
[Outcome of simultaneous radiochemotherapy of anal carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1997 |
Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cell Survival; Dose-Response Relationship, Drug; | 1997 |
Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Ad | 1997 |
Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 1998 |
Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic | 1998 |
Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Adhesion; Drug Resistance, Neoplasm; | 1998 |
7-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells.
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Interactions; | 1998 |
Perivesical fat necrosis after adjuvant intravesical chemotherapy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemo | 1999 |
[Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Co | 1999 |
[Long-term effects on recurrence and mortality in superficial urothelioma of the bladder treated with endovesical chemotherapy].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 1999 |
Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Division; Culture Techniques; Drug Screeni | 1999 |
Induction of apoptosis by mitomycin-C in an ex vivo model of bladder cancer.
Topics: Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Transitional Cell; Dose-Response Relationship, Dr | 2000 |
[Arterial infusion chemotherapy for patients with advanced and moderately advanced cancer of urinary bladder].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin c.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Human | 2000 |
The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Deami | 2000 |
Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity.
Topics: Antibiotics, Antineoplastic; Apoptosis; Autocrine Communication; Carcinoma, Transitional Cell; Cell | 2001 |
The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.
Topics: Apoptosis; Carcinoma, Transitional Cell; Down-Regulation; Genes, bcl-2; Humans; Mitomycin; Oligonucl | 2001 |
Re: methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
Topics: Administration, Intravesical; Antineoplastic Agents; Black or African American; Carcinoma, Transitio | 2001 |
Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antigens, Neop | 2001 |
Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitio | 2001 |
Intravesical immunotoxin as adjuvant therapy to prevent the recurrence of bladder cancer.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Ca | 2000 |
Recurrence of superficial bladder tumours after transurethral resection.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Doxorubicin; Fem | 1992 |
[Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 1992 |
Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
Topics: Administration, Intravesical; BCG Vaccine; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemothe | 1992 |
Superficial bladder disease: case studies and therapeutic advances.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Ca | 1992 |
Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; | 1992 |
Some aspects in treatment of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; | 1992 |
Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma.
Topics: Administration, Intravesical; Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middl | 1992 |
Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; | 1992 |
Combined chemoradiation therapy for anal cancer. A report of 56 cases.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1992 |
Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results.
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Administration S | 1992 |
Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Interferon-alpha; Mito | 1992 |
Bladder cancer chemotherapy: is response of squamous tumours different to that of transitional cell tumours?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1991 |
Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cell Line; Chloroquine; Cisplatin; Cytotoxici | 1992 |
The effect of pH on the in vitro colony forming ability of transitional cell carcinoma cells treated with various chemotherapeutic agents: implications for in vivo therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Humans; Hydrogen-Ion | 1992 |
Value of bladder wash cytology in the follow-up of patients with bladder carcinoma receiving intravesical chemoprophylaxis with mitomycin C.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurrence, | 1991 |
Intravesical chemotherapy for superficial carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Female; | 1991 |
Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Cystectomy; Female; Humans; Hypert | 1991 |
Dermatitis due to mitomycin C bladder instillations: study of 2 cases.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 1991 |
Cultured human bladder tumors for pharmacodynamic studies.
Topics: Antineoplastic Agents; Autoradiography; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Dose | 1991 |
In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1991 |
[Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy].
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubi | 1991 |
Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Co | 1991 |
[Effect of etoposide orally administered every other day for the prevention of recurrence of bladder tumor].
Topics: Administration, Intravesical; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined | 1990 |
Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; | 1990 |
[Balloon-occluded arterial infusion as chemotherapy in bladder cancer--long-term results].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1990 |
Eosinophilic cystitis and allergy to mitomycin-C.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cystitis; Eosinophilia; Female; Humans; M | 1990 |
[Prophylaxis of recurrence of superficial bladder tumor by diluted postoperative continuous intravesical instillation of anti-tumor solutions].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Transitional Cell; Doxorubicin; Female; Hu | 1985 |
[A study of postoperative adjuvant chemotherapy of advanced urinary epithelial cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell; Cispl | 1988 |
Combined intracavitary and external beam irradiation for superficial transitional cell carcinoma of the bladder: an alternative to cystectomy for patients with recurrence after intravesical chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Transitional Cell; C | 1989 |
Treatment modalities in superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Doxo | 1989 |
Preoperative intra-arterial infusion chemotherapy for patients with bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1989 |
Combination of hyperthermia and cytostatics in the treatment of bladder cancer.
Topics: Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Hyperthermia, Induced; Infusions, I | 1989 |
[A case report of bilateral liver metastasis from rectal cancer effectively treated with continuous infusion of anti-cancer drugs through hepatic artery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Carcinoma, Transitional Cell; Cisplat | 1989 |
Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; M | 1989 |
Renal failure after intravesical mitomycin C.
Topics: Acute Kidney Injury; Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; | 1989 |
[Effects of mitomycin C perfusion after bladder tumor surgery].
Topics: Administration, Intravesical; Adult; Aged; Carcinoma, Transitional Cell; Chemotherapy, Cancer, Regio | 1989 |
Transitional explant reduction assay--a new in vitro testing system for intravesical chemotherapy.
Topics: Carcinoma, Transitional Cell; Cisplatin; Colony-Forming Units Assay; Doxorubicin; Drug Evaluation; D | 1986 |
[Transcatheter arterial embolization therapy of recurrent pelvic cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Catheterization | 1986 |
Percutaneous management of upper tract transitional cell carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Electrosurgery; Humans; Kidney Neoplasms; Male; Mitomycin; Mitom | 1986 |
Carcinogenesis in mammalian urothelium: changes induced by non-carcinogenic substances and chronic indwelling catheters.
Topics: Animals; Carcinoma in Situ; Carcinoma, Papillary; Carcinoma, Transitional Cell; Catheters, Indwellin | 1986 |
Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Topics: Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cisplatin; Cystoscopy; Drug Evaluation; Dru | 1986 |
Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cytodiagnosis; Follow-Up Studies; Humans; Middle Aged; Mitomycin | 1986 |
Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 1986 |
Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Colony-Forming Units Assa | 1986 |
Treatment of urothelial carcinoma of the upper urinary tract following prostatocystectomy with mitomycin C instillation in the ileal loop.
Topics: Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Ileum; Kidney Neoplasms; Male | 1986 |
Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Doxorubicin; Epirubicin; | 1986 |
[Lung parenchyma disease following instillation of mitomycin C in the bladder].
Topics: Administration, Intravesical; Adult; Carcinoma, Transitional Cell; Humans; Lung Diseases; Male; Mito | 1986 |
Cytomorphological lesions induced by chemotherapeutic agents in transitional cell carcinoma in vitro.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cells, Cultured; Cisplatin; Doxorubicin; Humans | 1986 |
Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Ethoglucid; Humans; Methotrexate; Mitomy | 1986 |
Distilled water versus chemotherapeutic agents for transitional bladder carcinoma.
Topics: Carcinoma, Transitional Cell; Cell Survival; Humans; In Vitro Techniques; Mitomycin; Mitomycins; Neo | 1986 |
[Intra-arterial infusion chemotherapy for poor-risk patients with locally advanced bladder cancer--clinical assessment of five cases].
Topics: Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Injection | 1987 |
Feasibility of non-surgical definitive management of anal canal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1987 |
Percutaneous management of renal pelvic tumors: a treatment option in selected cases.
Topics: Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Femal | 1987 |
Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; | 1987 |
[Pulmonary fibrosis following instillation of mitomycin C in the urinary bladder].
Topics: Administration, Intravesical; Adult; Carcinoma, Transitional Cell; Humans; Male; Mitomycin; Mitomyci | 1987 |
In vitro drug sensitivity studies in human transitional cell carcinoma of the bladder.
Topics: Carcinoma, Transitional Cell; Clone Cells; Colony-Forming Units Assay; Culture Techniques; Dimethyl | 1987 |
[Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1987 |
Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Contracture; Female; Humans; Middle Aged | 1987 |
Adjuvant chemotherapy for invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Transitional Cell; Cispl | 1987 |
Treatment of superficial papillary transitional cell carcinoma of the ureter by vesicoureteral reflux of mitomycin C.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Male; M | 1987 |
Bladder wall calcification after topical mitomycin C.
Topics: Administration, Intravesical; Aged; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Ther | 1987 |
Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Do | 1987 |
[Prophylactic intravesical chemotherapy in bladder tumors after surgery of upper tract urothelial carcinoma].
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilq | 1987 |
Allergy to mitomycin C complicating topical administration for urothelial cancer.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Cystitis; Drug Hypersensitivity; E | 1987 |
Effect of continuous intravesical infusion of low-concentrated mitomycin-C on bladder carcinogenesis in rats treated with N-butyl-N-4-hydroxybutyl-nitrosamine.
Topics: Administration, Intravesical; Animals; Butylhydroxybutylnitrosamine; Carcinoma, Papillary; Carcinoma | 1988 |
Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell | 1988 |
[Clinical studies of the treatment of bladder tumor and its effects--experience in 86 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Tr | 1988 |
Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Transitional Cell; Cystosco | 1985 |
Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1985 |
Intravesical mitomycin C therapy for superficial bladder cancer. Report of a multicentre phase II study.
Topics: Carcinoma, Transitional Cell; Cystitis; Drug Evaluation; Humans; Mitomycin; Mitomycins; Skin Disease | 1985 |
Mitomycin-C induced improvement in superficial bladder tumors: a morphologic and immunohistochemical evaluation.
Topics: Biopsy; Carcinoma, Transitional Cell; Humans; Isoantigens; Mitomycin; Mitomycins; Urinary Bladder; U | 1985 |
Plasma levels during intravesical instillation of mitomycin-C.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Urinary Bla | 1985 |
Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Follow-U | 1985 |
Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Follow-Up Studies; Hum | 1985 |
Chemotherapy for bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1985 |